Difluorosubstituted heterocyclic compounds and the use thereof in the form of components in liquid crystalline media

Information

  • Patent Grant
  • 7648742
  • Patent Number
    7,648,742
  • Date Filed
    Tuesday, July 5, 2005
    19 years ago
  • Date Issued
    Tuesday, January 19, 2010
    15 years ago
Abstract
The invention relates to compounds of formula (I), wherein a, b, c, d, e, R1, R2, A1, A2, A3, A4, Y1, Y2, Y3, Z1, Z2, Z3, Z4 and are such as defined in claim 1, to a method for the production thereof, intermediates for the production and the thereof in the form of components in liquid crystalline media and to electrooptic display elements containing said liquid crystalline media.
Description

The present invention relates to difluorosubstituted heterocyclic compounds, a process for their preparation, intermediate compounds for a process for their preparation, their use as components in liquid crystalline media and electrooptical display elements which comprise these liquid crystalline media. In particular, the invention relates to difluoro substituted heterocyclic compounds having negative dielectric anisotropy.


Liquid crystals have found a wide field of application since the first commercially usable liquid crystalline compounds were found approximately 30 years ago. Known areas of application are, in particular, indicator displays for timepieces and pocket calculators and large display panels, such as are used in railroad stations, airports and sports arenas. Further areas of application are displays of portable computers and navigation systems and also television and video applications. High demands on switching times and the contrast of the images are made, in particular for the last-mentioned applications.


The spatial arrangement of the molecules in a liquid crystalline medium causes many of its properties to be direction-dependent. Of importance for use in liquid crystal displays here are, in particular, the anisotropies in the optical, dielectric and electromechanical behavior. Depending on whether the molecules are oriented with their longitudinal axes perpendicular or parallel to the two plates of a capacitor, this has a different capacity; the dielectric constant ∈ of the liquid crystalline medium is thus of different sizes for the two orientations. Substances whose dielectric constant on perpendicular orientation of the molecular longitudinal axes to the condenser plates is greater than on parallel arrangement are designated as dielectrically positive. In other words: the dielectric constant ∈ parallel to the molecular longitudinal axes is greater than the dielectric constant ∈ perpendicular to the molecular longitudinal axes, thus the dielectric anisotropy Δ∈=∈−∈ is greater than zero. Most liquid crystals which are used in conventional displays come into this group.


For dielectric anisotropy, both the polarizability of the molecule and permanent dipole moments play a role. On applying a voltage to the display, the longitudinal axis of the molecules is aligned such that the greater of the dielectric constants is effective. The strength of the interaction with the electric field depends in this case on the difference between the two constants. In the case of small differences, higher switching voltages are necessary than in the case of large ones. By means of the incorporation of suitable polar groups, such as, for example, of nitrile groups or fluorine, into the liquid crystal molecules a wide range of working voltages can be realized.


In the case of the mesogenic or liquid crystalline molecules used in the conventional liquid crystal displays, the dipole moment oriented along the molecular longitudinal axis is greater than the dipole moment oriented perpendicularly to the molecular longitudinal axis. The orientation of the greater dipole moment along the longitudinal axis of the molecule also determines the orientation of the molecule in a liquid crystal display in the field-free state. In the case of the most widespread TN cells (derived from “twisted nematic”), a liquid crystalline layer only approximately 5 to 10 μm thick is arranged between two plane-parallel glass plates, onto which in each case is evaporated an electrically conductive, transparent layer of tin oxide or indium-tin oxide (ITO) as an electrode. Between these films and the liquid crystalline layer is situated a likewise transparent orientation layer, which usually consists of a plastic (e.g. polyimides). It serves to bring the longitudinal axes of the adjacent crystalline molecules into a preferred direction by means of surface forces, such that in the voltage-free state they lie flat on the inside of the display surface uniformly with the same orientation or with the same small tilt angle. On the outside of the display, two polarization films which only allow linearly polarized light to enter and emerge are applied in a specific arrangement.


Using liquid crystals in which the greater dipole moment is oriented parallel to the longitudinal axis of the molecule, very efficient displays have already been developed. Here, mixtures of 5 to 20 components are usually used in order to achieve an adequately wide temperature range of the mesophase and also short switching times and low threshold voltages. The strong viewing angle dependence, however, still causes difficulties in liquid crystal displays such as are used, for example, for laptops. The best image quality can be achieved when the surface of the display is perpendicular to the viewing direction of the observer. If the display is tilted relative to the direction of observation, the image quality is drastically impaired under certain circumstances. For greater comfort, efforts have been made to make the angle as great as possible in order that the display can be tilted from the viewing direction of an observer without significant reduction of the image quality. More recently, for the improvement of viewing angle dependence, experiments have been undertaken to employ liquid crystalline compounds whose dipole moment perpendicular to the molecular longitudinal axis is greater than parallel to the longitudinal axis of the molecule. The dielectric anisotropy Δ∈ is negative. In the field-free state, these molecules are orientated perpendicular to the glass surface of the display. By realization of a number of domains, it was possible using liquid crystalline media having negative dielectric anisotropy to achieve an improvement in the viewing angle dependence. Shorter switching times in displays and better contrasts can also be achieved using this technology. Displays of this type are designated as VA-TFT displays (derived from: “vertically aligned”).


Development in the field of liquid crystalline materials is by far still not complete. For the improvement of the properties of liquid crystalline display elements, it is constantly being attempted to develop novel compounds which make possible optimization of displays of this type.


B. Zajc and M. Zupan, J. Org. Chem. 1990, 55, 1099-1102, describe the preparation of the following benzo-chroman derivatives:




embedded image



where Y is hydrogen or fluorine and X is hydrogen, fluorine or chlorine. Mesogenic or liquid crystalline properties of these compounds or an appropriate use are not disclosed.


An object of the present invention is therefore to make available compounds having advantageous properties for use in liquid crystalline media. In particular, they should have a negative dielectric anisotropy which makes them particularly suitable for use in liquid crystalline media for VA displays.


This object is achieved according to the invention by compounds of the general formula I




embedded image



in which:

  • a, b, c, d and e independently of one another are 0 or 1;
  • R1 and R2 independently of one another are hydrogen, —F, —Cl, —Br, —I, —CN, —SCN, —NTS, —SF5, an alkanyl, alkoxy, alkenyl or alkynyl having up to 15 carbon atoms, which is unsubstituted, monosubstituted by —CN or —CF3 or monosubstituted or polysubstituted by F, Cl, Br and/or I, where in these radicals one or more CH2 groups can also in each case independently of one another be replaced by —O—, —S—, —SO2—, —CO—, —(CO)O—, —O(CO)— or —O(CO)O—, such that hetero-atoms are not directly linked, or are a polymer-izable group P;
  • Y1, Y2, and Y3 independently of one another are hydrogen, halogen, halogenated alkyl or halogenated alkoxy having 1 to 8 carbon atoms;
  • A1, A2, A3 and A4 independently of one another are 1,4-phenylene which can be unsubstituted or mono- to tetrasubstituted independently of one another by —CN, —F, —Cl, —Br, —I, C1-C6-alkanyl which can be unsubstituted or mono- or poly-substituted by fluorine and/or chlorine, C1-C6-alkoxy which can be unsubstituted or mono- or poly-substituted by fluorine and/or chlorine; 1,4-cyclohexylene, 1,4-cyclohexenylene or 1,4-cyclohexadienylene, in which —CH2— can independently of one another be replaced once or twice by —O— or —S— such that heteroatoms are not directly linked, and which can be unsubstituted or mono- or polysubstituted by —F, —Cl, —Br and/or —I;
  • Z1, Z2, Z3 and Z4 independently of one another are a single bond, —CF2O—, —OCF2—, —CH2CH2—, —CF2CF2—, —CF2CH2—, —CH2CF2—, —CHF—CHF—, —(CO)O—, —O(CO)—, —CH2O—, —OCH2—, —CF═CH—, —CH═CF—, —CF═CF—, —CH═CH— or —C≡C—; and
  • custom character in the oxygen heterocycle of the formula I is a C—C single bond and, if e is 1, can also be a C═C double bond;


    where Y2 is not hydrogen or fluorine and R2 is not hydrogen, fluorine or chlorine if at the same time a, b, c and d are 0 and e is 1 and R1 is hydrogen and Y1 and Y3 are both hydrogen and custom character is a single bond.


The compounds preferably have a negative Δ∈ and are therefore particularly suitable for use in VA-TFT displays. Preferably, the compounds according to the invention have a Δ∈<−2 and particularly preferably a Δ∈<−5. They show very good compatibility with the customary substances used in liquid crystal mixtures for displays.


Furthermore, the compounds of the formula I according to the invention have suitable values of the optical anisotropy Δn, in particular for use in VA-TFT displays. Preferably, the compounds according to the invention have a Δn of greater than 0.02 and less than 0.40, preferably of greater than 0.04 and less than 0.15.


The further physical, physicochemical or electro-optical parameters of the compounds according to the invention are also advantageous for use of the compounds in liquid crystalline media. The compounds in particular have an adequate breadth of the nematic phase and a good low-temperature and long-term stability and also adequately high clear points.


The compounds of the formula I according to the invention are furthermore suitable for the preparation of further, optionally more complex mesogenic or liquid crystalline substances which possess a structural element having a benzo-fused and difluoro-substituted oxygen heterocycle.


The compounds of the formula I according to the invention are benzochroman derivatives, i.e. e=1 and custom character is a C—C single bond, benzochromene derivatives, i.e. e=1 and custom character is a C—C double bond, or benzofuran derivatives, i.e. e=0 and custom character is a C—C single bond which is linked directly to the aromatic ring. Benzochroman and benzochromene derivatives are preferred here, i.e. e is preferably 1. Benzochroman derivatives of the formula I are particularly preferred, i.e. e is 1 and custom character is a C—C single bond.


If R1 and R2 in formula I in each case independently of one another are an alkanyl radical and/or an alkoxy radical (alkyloxy radical) having 1 to 15 C atoms, these are straight-chain or branched. Preferably, each of these radicals is straight-chain, has 1, 2, 3, 4, 5, 6 or 7 C atoms and accordingly is preferably methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy or heptoxy.


R1 and R2 in formula I can in each case independently of one another also be an oxaalkyl radical, i.e. an alkanyl radical, in which at least one of the nonterminal CH2 groups of the alkanyl radical is replaced by —O—, preferably straight-chain 2-oxapropyl (=methoxymethyl), 2-(=ethoxymethyl) or 3-oxabutyl (=methoxyethyl), 2-, 3- or 4-oxapentyl, 2-, 3-, 4- or 5-oxahexyl, 2-, 3-, 4-, 5- or 6-oxaheptyl. Correspondingly, R1 and R2 in formula I can also independently of one another be thioalkanyl or sulfonalkanyl radicals, i.e. alkanyl radicals in which a CH2 group is replaced by —S— or —SO2—.


R1 and R2 in formula I can furthermore in each case independently of one another be an alkenyl radical having 2 to 15 C atoms, which is straight-chain or branched and has at least one C—C double bond. Preferably, it is straight-chain and has 2 to 7 C atoms. Accordingly, it is preferably vinyl, prop-1- or prop-2-enyl, but-1-, 2- or but-3-enyl, pent-1-, 2-, 3- or pent-4-enyl, hex-1-, 2-, 3-, 4- or hex-5-enyl, hept-1-, 2-, 3-, 4-, 5- or hept-6-enyl. It the two C atoms of the C—C double bond are substituted, the alkenyl radical can be present as an E and/or Z isomer (trans/cis). In general, the respective E isomers are preferred.


In the same manner as in the case of an alkanyl radical, at least one of the CH2 groups in an alkenyl radical can be replaced by oxygen, sulfur or —SO2—. In the case of replacement by —O—, an alkenyloxy radical (having a terminal oxygen) or an oxaalkenyl radical (having a nonterminal oxygen) is then present.


R1 and R2 in formula I can independently of one another also be an alkynyl radical having 2 to 15 C atoms, which is straight-chain or branched and has at least one C—C triple bond.


R1 and R2 in formula I can in each case independently of one another be an alkanyl radical having 1 to 15 C atoms, in which one CH2 group is replaced by —O— and one by —CO—, where these are preferably adjacent. This thus comprises an acyloxy group —CO—O— or an oxy-carbonyl group —O—CO—. Preferably, this radical is straight-chain and has 2 to 6 C atoms. The following of these radicals are preferred here: acetyloxy, propionyloxy, butyryloxy, pentanoyloxy, hexanoyloxy, acetyloxymethyl, propionyloxymethyl, butyryloxymethyl, pentanoyloxymethyl, 2-acetyloxyethyl, 2-propionyloxy-ethyl, 2-butyryloxyethyl, 2-acetyloxypropyl, 3-prop-ionyloxypropyl, 4-acetyloxybutyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butbxycarbonyl, pentoxycarbonyl, methoxycarbonylmethyl, ethoxycarbonyl-methyl, propoxycarbonylmethyl, butoxycarbonylmethyl, 2-(methoxycarbonyl)ethyl, 2-(ethoxycarbonyl)ethyl, 2-(propoxycarbonyl)ethyl, 3-(methoxycarbonyl)propyl, 3-(ethoxycarbonyl)propyl or 4-(methoxycarbonyl)butyl. Furthermore, an alkanyl radical can also have an —O—CO—O— unit. The replacement of a CH2 group by only one —CO— group (carbonyl function) is also possible.


R1 and R2 in formula I can in each case independently of one another be an alkenyl radical having 2 to 15 C atoms, in which a CH2 group, preferably in the neighborhood of an unsubstituted or substituted —C═C— unit, is replaced by —CO—, —CO—O—, —O—CO— or —O—CO—O—, where this radical can be straight-chain or branched. Preferably, the radical is straight-chain and has 4 to 13 C atoms. Acryloyloxymethyl, 2-acryloyloxyethyl, 3-acryloyloxypropyl, 4-acryloyloxybutyl, 5-acryloyloxy-pentyl, 6-acryloyloxyhexyl, 7-acryloyloxyheptyl, 8-acryloyloxyoctyl, 9-acryloyloxynonyl, methacryloyl-oxymethyl, 2-methacryloyloxyethyl, 3-methacryloyloxy-propyl, 4-methacryloyloxybutyl, 5-methacryloyloxy-pentyl, 6-methacryloyloxyhexyl, 7-methacryloyloxyheptyl or 8-methacryloyloxyoctyl are particularly preferred here. Correspondingly, a CH2 group in an alkynyl radical, in particular in the neighborhood of a substituted —C≡C— unit, can also be replaced by —CO—, —CO—O—, —O—CO— or —O—CO—O—.


R1 and R2 in formula I can in each case independently of one another be an alkanyl radical in which two or more CH2 groups can be replaced by —O— and/or —CO—O—, where these can be straight-chain or branched. Preferably, it is branched and has 3 to 12 C atoms.


R1 and R2 in formula I can in each case independently of one another be an alkanyl radical or alkoxy radical having 1 to 15 C atoms, which is monosubstituted by —CN or —CF3 or a correspondingly substituted alkenyl radical or alkynyl radical having 2 to 15 C atoms, where these are preferably straight-chain. The substitution by —CN or —CF3 is possible in any desired position.


R1 and R2 in formula I can in each case independently of one another be an alkanyl radical or alkoxy radical having 1 to 15 C atoms, which is monosubstituted or polysubstituted by F, Cl, Br and/or I, or an alkenyl radical, alkenyloxy radical or alkynyl radical having 2 to 15 C atoms, where these radicals are preferably straight-chain and halogen is preferably —F and/or —Cl. In the case of polysubstitution halogen is preferably —F. The resulting radicals also include perfluorinated radicals such as —CF3. The mono- or polyfluorinated radicals are also termed “fluoroalkyl”, “fluoroalkanyl”, “fluoroalkoxy”, “fluoroalkenyl”, “fluoroalkenyloxy” and “fluoroalkynyl”. In the case of monosubstitution the fluorine or chlorine substituent can be in any desired position, preferably in the ω-position.


R1 and R2 in formula I can also in each case independently of one another be —F, —Cl, —Br, —I, —CN, —SCN, —NCS OR —SF5.


R1 and R2 in formula I can also independently of one another be a polymerizable or reactive group P; this is distinguished in that it is able to react in a polymerization reaction, e.g. a free radical or ionic chain polymerization, or in a polyaddition or polycondensation, or in that it can be grafted onto a polymer backbone in a manner analogous to a polymerization reaction, for example by condensation or addition. Particularly preferred groups P are those for chain polymerization reactions such as free radical, anionic or cationic polymerization. Very particularly preferred polymerizable groups P are those which comprise a C—C double bond or a C—C triple bond or which can polymerize with ring opening, e.g. oxetanes or epoxides.


These very particularly preferred polymerizable groups P are selected from the group PI, which comprises:


CH2═CW4—COO—,




embedded image



CH2═CW5—(O)k1—, CH3—CH═CH—O—, (CH2═CH)2CH—OCO—, (CH2═CH—CH2)2CH—OCO—, (CH2═CH)2CH—O—, (CH2═CH—CH2)2N, (CH2═CH—CH2)2N—CO—, HO—CW5W6—, HS—CW5W6—, HW5N—, HO—CW5W6—NH—, CH2═CW4—CO—NH—, CH2═CH—(COO)k1-Phe-(O)k2—, Phe-CH—═CH—, HOOC—, OCN— and W7W8W9Si—, where W4 is H, Cl, CN, phenyl or alkyl having 1 to 5 carbon atoms, in particular H, Cl or CH3, W5 and W6 independently of one another are H or alkyl having 1 to 5 carbon atoms, in particular methyl, ethyl or n-propyl, W7, W8 and W9 independently of one another are Cl, oxaalkyl or oxacarbonylalkyl having 1 to 5 carbon atoms, Phe is 1,4-phenylene which can optionally be monosubstituted or polysubstituted by halogen, and k1 and k2 independently of one another are 0 or 1.


Among these groups P′, CH2═CH—COO—, CH2═C(CH3)—COO—, CH2═CCH—, CH2═CH—O—, (CH2═CH)2CH—OCO—, (CH2═CH)2CH—O— and




embedded image



are extremely preferred, where a vinyl group, an acrylate group, a methacrylate group, an oxetane group or an epoxy group, especially an acrylate or methacrylate group, may expressly be mentioned. Acrylate and oxetane groups are particularly preferred.


The polymerizable group P or P′ can also contain one of the suitable spacers known in the prior art between the actual reactive polymerizable group and the radical or the ring to which the group P or P′ is linked, inter alia ethylene, propylene or butylene. The polymerizable group P is then, for example, a group P′-spacer-, where P′ is one of the abovementioned polymerizable functional radicals P′ and “spacer” is one of the spacers known in the prior art.


Preferably, R1 and R2 independently of one another are alkanyl, alkenyl or alkoxy, in each case having up to 8 carbon atoms, hydrogen, fluorine or chlorine, particularly preferably alkanyl, alkoxy, fluorine or hydrogen. In particular, R1 is alkoxy or fluorine and R2 is alkanyl.


Y1, Y2 and Y3 are preferably independently of one another fluoroalkanyl, fluoroalkenyl, fluoroalkenyloxy or fluoroalkoxy, in each case having up to 4 carbon atoms, hydrogen, fluorine or chlorine. Particularly preferably, Y2 and Y3 are in each case hydrogen and Y1 is hydrogen, F, C1 or CF3. Very particularly preferably, Y2 and Y3 are hydrogen and Y1 is hydrogen or fluorine, in particular fluorine.


The rings A1, A2, A3 and 4 are preferably selected independently of one another from the group which comprises




embedded image


Among the phenylene rings,




embedded image



are preferred here.


Z1, Z2, Z3 and Z4 are independently of one another preferably a single bond, —CF2O—, —OCF2—, —CH2CH2—, —CF2CF2— or —CH═CH—, particularly preferably a single bond, —CF2O— or —OCF2—, in particular a single bond.


In addition to the central benzo-fused oxygen heterocycle, the compounds of the formula I according to the invention either have one further or two further ring systems of the formulae A1, A2, A3 and/or A4, i.e. a+b+c+d is preferably 1 or 2. If only one further ring is present, i.e. a+b+c+d=1, it can either be present on the “left” side of the molecule of the formula I, i.e. be linked with the central aromatic ring, or on the “right” side of the molecule of the formula I, i.e. be linked with the central heterocycle. The one ring is preferably linked to the central heterocycle. If two further rings are present, they can both be present on the “left” side of the molecule of the formula I or both be present on the “right” side of the molecule of the formula I, or one of the two radicals is linked to the central aromatic ring, while the other is linked to the central O heterocycle. Here, “be linked” means that the respective ring is bonded to the central ring system either directly via a single bond or indirectly via a bridge Z, which is not a single bond. Particularly preferably, only one further ring is present or, in the case that two further rings are present, in each case one of the rings is linked to the central aromatic ring or to the central heterocycle.


A preferred embodiment of the invention are benzo-chroman derivatives of the formula I, in which a and d are both 0; b is 0 or 1, c is 1; R1, if b is 0, is alkanyl or alkoxy, and if b is 1, is F, alkanyl or alkoxy; R2 is alkanyl or alkoxy; A2, if b is 1, is




embedded image



A3 is




embedded image



Z2, if b is 1, is a single bond; and Z3 is a single bond.


Preferred benzochroman derivatives of the formula I according to the invention, in which a+b+c+d is 0, are shown by the general formula IA:




embedded image



where R1, R2, Y1, Y2 and Y3 have the same meanings and the same preferred meanings as defined above for formula I.


Preferred benzochroman derivatives of the formula I according to the invention, in which a+b+c+d is 1, are shown by the general formulae IB and IC:




embedded image



where R1, R2, A2, A3, Z2, Z3, Y1, Y2 and Y3 have the same meanings and the same preferred meanings as defined above for formula I.


Preferred benzochroman derivatives of the formula I according to the invention, in which a+b+c+d is 2, are shown by the general formulae ID, IE and IF:




embedded image



where, R1, R2, A1, A2, A3, Z1, Z2, Z3, Z4, Y1, Y2 and Y3 have the same meanings and the same preferred meanings as defined above for formula I.


Among the compounds of the formulae IA to IF according to the invention, compounds of the formulae IB, IC and IF are particularly preferred, especially compounds of the formulae IC and IF.


Exemplary compounds of the formula IB are the following compounds:




embedded image



where n and m independently of one another are 1, 2, 3, 4, 5, 6, 7 or 8, where in the formulae IB-a and IB-c n can also be 0 and in all formulae IB-a to IB-D m can also be 0.


Exemplary compounds of the formula IC are the following compounds:




embedded image



where n and m independently of one another are 1, 2, 3, 4, 5, 6, 7 or 8, where in the formulae IC-a, IC-b, IC-c and IC-e, n can also be 0 and in all formulae IC-a to IC-f, m can also be 0.


Exemplary compounds of the formula IF are the following compounds:




embedded image


embedded image



where n and m independently of one another are 1, 2, 3, 4, 5, 6, 7 or 8, where in the formulae IF-a, IF-c, IF-e, IF-f, IF-h and IF-j, n can also be 0 and in the formulae IF-a, IF-b, IF-e, IF-f, IF-g and IF-j, m can also be 0.


The compounds of the general formula I are prepared by methods known per se, as are described in the literature (e.g. in the standard works such as Houben-Weyl, Methoden der organischen Chemie [Methods of organic chemistry], Georg-Thieme-Verlag, Stuttgart), namely under reaction conditions which are known and suitable for the reactions mentioned. Use can be made here of variants which are known per se, but not mentioned here in more detail. The starting substances can optionally also be formed in situ in such a way that they are not isolated from the reaction mixture, but immediately reacted further to give the compounds of the general formula I. The starting substances can be obtained according to generally accessible literature procedures or are commercially available.


The compounds of the formula I according to the invention, however, are also accessible according to a process which is a further subject of the present invention. The process according to the invention is characterized in that a compound of the general formula II:




embedded image



in which

  • a, b, c, d, e, R1, R2, A1, A2, A3, A4, Y1, Y2, Y3, Z1, Z2, Z3, Z4 and custom character are as defined for formula I and preferably have the same preferred meanings as for formula I;
  • W1 is —SR3 and
  • W2 is —SR4;


    or
  • W1 and W2 together are ═S or —S—W3—S—,


    where
  • R3 and R4 independently of one another is alkyl having 1 to 8 carbon atoms; and
  • W3 is a bivalent organic radical having at least two carbon atoms;


    is reacted with a fluoride-releasing compound in the presence of an oxidant.


Here, the fluoride-releasing compound is preferably selected from the group which comprises HF, pyridine-hydrogen fluoride complexes, triethylamine trishydro-fluoride (Et3N.3HF) and tetrabutylammonium dihydrogen-trifluoride. Pyridine-hydrogen fluoride complexes and triethylamine trishydrofluoride, in particular triethylamine trishydrofluoride, are particularly preferred.


The oxidant is preferably selected from the group which comprises dimethyldibromohydantoin (DBH), N-chloro-succinimide (NCS), N-bromosuccinimide (NBS), N-iodo-succinimide (NIS), chlorine, bromine, SO2Cl2, SO2ClF, NOBF4 and chloramine T. The oxidant dimethyldibromo-hydantoin, N-bromosuccinimide or bromine, in particular DBH, is particularly preferred.


The exact choice of the reaction conditions of the process according to the invention is not critical per se, provided the reaction of the compound of the formula II to give the compound of the formula I according to the invention proceeds rapidly enough and with adequate selectivity without undesired reaction of reactants, products and reagents. These reaction conditions follow from those of analogous oxidative fluorodesulturization reactions for the introduction of —CF2O— bridges into open-chain compounds, such as are described, inter alia, in P. Kirsch et al, Angew. Chem. 2001, 113, 1528-1532; WO 01/64667 A1, WO 02/48073 A1 and WO 03/033619 A1.


The fluoride-releasing compound is customarily employed in an amount such that—based on the compound of the formula II to be fluorinated approximately 2 to approximately 50 mol equivalents, preferably approximately 5 to approximately 25 mol equivalents and particularly preferably approximately 10 to approximately 20 mol equivalents of fluoride ions are released. If, for example, triethylamine trishydro-fluoride is used as the fluoride-releasing compound, which releases 3 equivalents of fluoride from 1 equivalent of the compound, this reagent is employed in an amount from approximately 0.65 to approximately 16.7 mol equivalents of the compound, based on the compound of the formula II to be reacted, preferably in an amount from approximately 1.65 to approximately 8.4 mol equivalents and particularly preferably in an amount from approximately 3.3 to approximately 6.6 mol equivalents. The oxidant is customarily used in an amount from approximately 2 to approximately 10 mol equivalents—based on the compound of the formula II to be reacted—, particularly preferably in an amount from approximately 3 to approximately 7 mol equivalents and in particular in an amount from approximately 4.5 to approximately 5.5 mol equivalents.


The process according to the invention can be carried out solvent-free and is preferably carried out in a solvent or a mixture of one, two, three or more solvents which is adequately inert to reactants, products and reagents. Preferably, these are polar solvents or solvent mixtures such as ethers, e.g. diethyl ether, methyl tert-butyl ether and tetra-hydrofuran (THF) and haloalkanes, e.g. dichloro-methane, trichloromethane and trichloroethylene. Particularly preferably, an individual solvent is used, in particular dichloromethane.


The process according to the invention is carried out in a temperature range from approximately −100° C. to approximately 50° C., depending on the reaction rate, selectivity and exothermicity of the reaction.


The reaction period is likewise especially determined by the rate at which the reaction according to the invention proceeds, and is customarily between 10 min and 2 days, preferably between 1 hour and 24 hours and in particular between 2 hours and 6 hours.


The compounds of the formula II defined above employed in the process according to the invention for the preparation of the compounds of the formula I according to the invention are for their part novel and a further subject of the present invention; here, the radicals, substituents and parameters a, b, c, d, e, R1, R2, A1, A2, A3, A4, Y1, Y2, Y3, Z1, Z2, Z3, Z4 and custom character assume the same meanings and preferably the same preferred meanings as for formula I. Excluded from this is the compound of the formula II, in which a, b, c and d simultaneously are all 0 and e is 1 and R1 and R2 are both hydrogen and Y1, Y2 and Y3 are all hydrogen and custom character is a C—C single bond and W1 and W2 are together —S—W3—S— where W3 is equal to —CH2—CH2— (E. J. Corey, D. J. Beamers, J. Am. Chem. Soc. 1973, 95, 5829-5831). This compound is only excluded as such, but is employed according to the invention in the process according to the invention for the preparation of the corresponding compound of the formula I.


If W1 is —S—R3 and W2 is —S—R4, R3 and R4 independently of one another are preferably alkanyl radicals having 1, 2, 3, 4, 5 or 6 carbon atoms, in particular methyl, ethyl, n-propyl, i-propyl and n-butyl. R3 and R4 can be identical or different and are preferably identical.


If W1 and W2 together are —S—W3—S—, the bivalent organic radical W3 having at least two carbon atoms is preferably an alkylene bridge having 2, 3, 4, 5 or 6 carbon atoms in the bridge, where up to three of these carbon atoms in each case can have one or two further C1-C4-alkanyl substituents; it is also possible that two adjacent carbon atoms of the alkylene bridge for their part are part of a further ring or ring system, such as, for example, in




embedded image



Furthermore, W is preferably a benzene ring which can optionally have further substituents. Particularly preferably, W3 is ethylene (—CH2—CH2—) or propylene (—CH2—CH2—CH2—).


The compounds of the formula II according to the invention are for their part accessible in various ways from substances which are known from the literature or commercially obtainable. In a preferred embodiment, which is also a preferred embodiment of the process according to the invention for preparation of compounds of the formula I, the compound of the formula II is obtained from a lactone of the general formula III by reaction with a reagent which is obtainable by reaction of approximately 2 mol equivalents of trialkylaluminum with approximately 1 mol equivalent of HS—W3—SH and is preferably formed in situ. Here, the lactone has the following formula III




embedded image



in which a, b, c, d, e, R1, R2, A1, A2, A3, A4, Z1, Z2, Z3, Z4 and custom character are as defined for the formulae I and II.


Preferably, the trialkylaluminum employed is a trimethylaluminum. W3 in the dithiol HS—W3—SH has the same meaning and the same preferred meaning as in formula II.


The lactone of the formula III can be prepared, for example, as in or analogously to the following scheme 1:




embedded image


Here, the salicylaldehyde A condenses with acetic acid derivatives B to give the lactone C, which can now be employed for its part in the process according to the invention. Alternatively, the endocyclic double bond of C can be reduced under catalytic hydrogenation and the lactone D thus obtained.


A further process for the preparation of lactones employed according to the invention is shown in scheme 2:




embedded image


Here, the salicylaldehyde E is reacted with lithium ester enolates F to give G; by addition of acid, the OH group is eliminated with formation of a C—C double bond, which is subsequently catalytically hydrogenated. The resulting compound H is subsequently converted to the lactone D with acid in methanol or by heating.


A further synthesis (scheme 3) is especially suitable for the preparation of lactones of the formula III, in which c and d are both 0 and R2 is an alkyl radical:




embedded image


The reaction of A with malonic acid diester to give J takes place first, then hydrogenation to give K and reaction with a base and an alkyl halide R2-halogen to give L. Hydrolysis and decarboxylation finally yield the lactone D′.


A further process for the preparation of compounds of the formula I according to the invention or precursors for these is shown in two variants in scheme 4:




embedded image


In variant a), the ketone L is converted using the 2-trimethylsilyl-1,3-dithiane M and n-butyllithium and subsequent reaction with tetrabutylammonium fluoride into the ketene dithioketal which for its part is cyclized under acid catalysis to give the spiro compound O, which is a compound of the formula II. In variant b), the carboxylic acid derivative P is activated using thionyl chloride and then reacted with propane-1,3-dithiol in the presence of trifluoroacetic acid to give the salt Q, which for its part can be reacted with a fluoride-releasing compound and an oxidant to give the desired compound of the formula I.


Modifications and variations of the processes mentioned can be performed and carried out without problems by the person skilled in the act on the basis of his knowledge. The study of the attached examples will further illustrate these processes.


As already mentioned, the compounds of the general formula I can be used in liquid crystalline media.


The present invention therefore also relates to a liquid crystalline medium having at least two liquid crystalline compounds, comprising at least one compound of the general formula I, where according to the invention the benzochroman derivatives of the formula I with a, b, c, d equal to 0, R1, Y1 and Y3 equal to hydrogen and Y2 equal to hydrogen or fluorine and R2 equal to hydrogen, fluorine or chlorine, which are already known as such in the prior art, can be employed here.


The present invention also relates to liquid crystalline media comprising as further constituents, in addition to one or more compounds of the formula I according to the invention, 2 to 40, preferably 4 to 30, components. Particularly preferably, in addition to one or more compounds according to the invention these media contain 7 to 25 components. These further constituents are preferably selected from nematic or nematogenic (monotropic or isotropic) substances, in particular substances from the classes consisting of the azoxybenzenes, benzylideneanilines, biphenyls, terphenyls, 1,3-dioxanes, 2,5-tetrahydropyrans, phenyl or cyclohexyl benzoates, cyclohexanecarboxylic acid phenyl or cyclohexyl esters, phenyl or cyclohexyl esters of cyclohexylbenzoic acid, phenyl or cyclohexyl esters of cyclohexylcyclohexanecarboxylic acid, cyclohexylphenyl esters of benzoic acid, of cyclohexanecarboxylic acid, and of cyclohexylcyclohexane-carboxylic acid, phenylcyclohexanes, cyclohexyl-biphenyls, phenylcyclohexylcyclohexanes, cyclohexyl-cyclohexanes, cyclohexylcyclohexylcyclohexenes, 1,4-biscyclohexylbenzenes, 4′,4′-biscyclohexylbiphenyls, phenyl- or cyclohexylpyrimidines, phenyl- or cyclohexylpyridines, phenyl- or cyclohexyldioxanes, phenyl- or cyclohexyl-1,3-dithianes, 1,2-diphenylethanes, 1,2-dicyclohexylethanes, 1-phenyl-2-cyclohexylethanes, 1-cyclohexyl-2-(4-phenylcyclohexyl)ethanes, 1-cyclohexyl-2-biphenylethanes, 1-phenyl-2-cyclohexylphenyl-ethanes, optionally halogenated stilbenes, benzyl phenyl ethers, tolanes and substituted cinnamic acids. The 1,4-phenylene groups in these compounds can also be mono- or polyfluorinated.


The most important compounds suitable as further constituents of media according to the invention can be characterized by the formulae (1), (2), (3), (4) and (5):

R′-L-E-R″  (1)
R′-L-COO-E-R″  (2)
R′-L-OOC-E-R″  (3)
R′-L-CH2CH2-E-R″  (4)
R′-L-CF2O-E-R″  (5)


In the formulae (1), (2), (3), (4) and (5), L and E, which can be identical or different, are in each case independently of one another a bivalent radical from the group formed from -Phe-, -Cyc-, -Phe-Phe-, -Phe-Cyc-, -Cyc-Cyc-, -Pyr-, -Dio-, Thp-, -G-Phe- and -G-Cyc-, and their mirror images, where Phe is 1,4-phenylene unsubstituted or substituted by fluorine, Cyc is trans-1,4-cyclohexylene or 1,4-cyclohexenylene, Pyr is pyrimidine-2,5-diyl or pyridine-2,5-diyl, Dio is 1,3-dioxane-2,5-diyl, Thp is tetrahydropyran-2,5-diyl and G is 2-(trans-1,4-cyclohexyl)ethyl, pyrimidine-2,5-diyl, pyridine-2,5-diyl, 1,3-dioxane-2,5-diyl or tetra-hydropyran-2,5-diyl.


Preferably, one of the radicals L and E is Cyc or Phe. E is preferably Cyc, Phe or Phe-Cyc. Preferably, the media according to the invention contain one or more components selected from the compounds of the formulae (1), (2), (3), (4) and (5), in which L and E are selected from the group consisting of Cyc and Phe and simultaneously one or more components selected from the compounds of the formulae (1), (2), (3), (4) and (5) in which one of the radicals L and E is selected from the group Cyc and Phe and the other radical is selected from the group -Phe-Phe-, -Phe-Cyc-, -Cyc-Cyc-, -G-Phe- and -G-Cyc-, and optionally one or more components selected from the compounds of the formulae (1), (2), (3), (4) and (5) in which the radicals L and E are selected from the group consisting of -Phe-Cyc-, -Cyc-Cyc-, -G-Phe- and -G-Cyc-.


In a smaller subgroup of compounds of the formulae (1), (2), (3), (4) and (5), R′ and R″ are in each case independently of one another alkyl, alkenyl, alkoxy, alkoxyalkyl(oxaalkyl)alkenyloxy or alkanoyloxy having up to 8 C atoms. Below, this smaller subgroup is called group A and the compounds are designated by the subformulae (1a), (2a), (3a), (4a) and (5a). In most of these compounds, R′ and R″ are different from one another, where one of these radicals is usually alkyl, alkenyl, alkoxy or alkoxyalkyl(oxaalkyl).


In another smaller subgroup of the compounds of the formulae (1), (2), (3), (4) and (5) designated as group B, E is




embedded image


In the compounds of group B, which are designated by the subformulae (1b), (2b), (3b), (4b) and (5b), R′ and R″ have the meaning indicated in the case of the compounds of the subformulae (1a) to (5a) and are preferably alkyl, alkenyl, alkoxy or alkoxyalkyl(oxa-alkyl).


In a further smaller subgroup of the compounds of the formulae (1), (2), (3), (4) and (5), R″ is —CN. This subgroup is designated below as group C and the compounds of this subgroup are correspondingly described by subformulae (1c), (2c), (3c), (4c) and (5c) In the compounds of the subformulae (1c), (2c), (3c), (4c) and (5c), R′ has the meaning indicated in the case of the subformulae (1a) to (5a) and is preferably alkyl, alkenyl, alkoxy or alkoxyalkyl(oxa-alkyl).


In addition to the preferred compounds of groups A, B and C, other compounds of the formulae (1), (2), (3), (4) and (5) having other variants of the designated substituents are customary. All these substances are obtainable according to methods known in the literature or in analogy thereto.


In addition to the compounds of the general formula I according to the invention, the media according to the invention preferably contain one or more compounds from the groups A, B and/or C. The percentages by weight of the compounds from these groups in the media according to the invention are:

  • Group A: 0 to 90%, preferably 20 to 90%, in particular 30 to 90%
  • Group B: 0 to 80%, preferably 10 to 80%, in particular 10 to 70%
  • Group C: 0 to 80%, preferably 5 to 80%, in particular 5 to 50%.


The media according to the invention preferably contain 1 to 40%, particularly preferably 5 to 30%, of the compounds of the formula I according to the invention. Media comprising more than 40%, in particular 45 to 90%, of compounds of the formula I according to the invention are furthermore preferred. The media preferably contain one, two, three, four or five compounds of the formula I according to the invention.


Examples of the compounds of the formulae (1), (2), (3), (4) and (5) are the compounds listed below:




embedded image


embedded image



with Ra, Rb independently of one another —CpH2p+1 or —OCpH2p+1 and p=1, 2, 3, 4, 5, 6, 7 or 8 and L1, L2 independently of one another —H or —F,




embedded image


embedded image



with m, n independently of one another 1, 2, 3, 4, 5, 6, 7 or 8.


The preparation of the media according to the invention is carried out in a manner customary per se. As a rule, the components are dissolved in one another, preferably at elevated temperature. By means of suitable additives, the liquid crystalline phase of the present invention can be modified such that it can be used in all types of liquid crystal display elements which have hitherto become known. Additives of this type are known to the person skilled in the art and described in detail in the literature (H. Kelker/R. Hatz, Handbook Of Liquid Crystals, Verlag Chemie, Weinheim, 1980). For example, pleochroitic dyes can be added for the preparation of colored guest-host systems or substances can be added for the modification of the dielectric anisotropy, the viscosity and/or the orientation of the nematic phases.


Because of their negative Δ∈, the compounds of the formula I are suitable in particular for use in VA-TFT displays.


The present invention therefore also relates to electrooptical liquid crystal display elements comprising a liquid crystalline medium according to the invention.


The invention is explained in more detail below with the aid of exemplary embodiments without, however, being intended to be restricted thereby.


Above and below, Δn is the optical anisotropy (589 nm, 20° C.) and Δ∈ is the dielectric anisotropy (1 kHz, 20° C.).


In the context of the present invention, halogen is fluorine, chlorine, bromine and iodine.


In connection with the present invention, the expression “alkyl”—if not defined differently at another place in this description or in the claims—in its most general meaning is a straight-chain or branched, saturated or unsaturated aliphatic hydrocarbon radical having 1 to 15 (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15) carbon atoms; this radical is unsubstituted or monosubstituted or polysubstituted by fluorine, chlorine, bromine, iodine, carboxyl, nitro, —NH2, —N(alkanyl)2 and/or cyano, where the polysubstitution can take place by the same or by different substituents. The alkyl radical in the aliphatic hydrocarbon chain itself can also be functionalized.


If this alkyl radical is a saturated radical, it is also designated as “alkanyl”. Furthermore, the expression “alkyl” also comprises unsubstituted hydrocarbon radicals or corresponding hydrocarbon radicals which are identically or differently mono- or polysubstituted, in particular by F, Cl, Br, I and/or —CN, in which one or more CH2 groups can be replaced by —O— (“alkoxyl”, “oxaalkyl”), —S— (“thioalkyl”), —SO2—, —CH═CH—, (“alkenyl”), C≡C— (“alkynyl”), —CO—, —CO—C— or —O—CO— such that heteroatoms (O,S) in the chain are not linked directly to one another. Preferably, alkyl is a straight-chain or branched unsubstituted or substituted alkanyl, alkenyl or alkoxy radical having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms. If alkyl is an alkanyl radical, this is preferably methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, n-pentyl, neopentyl, n-hexyl, n-heptyl, n-octyl; CF3, CHF2, CH2F, CF2CF3. Particularly preferably, the alkanyl radical is straight-chain and unsubstituted or substituted by F.


As in an alkyl radical one or more CH2 groups can be replaced by —O—, the expression “alkyl” also comprises “alkoxy” or “oxaalkyl” radicals. Alkoxy is to be understood as meaning an O-alkyl radical in which the oxygen atom is bonded directly to the group substituted by the alkoxy radical or to the substituted ring and alkyl is defined as above; preferably alkyl is then alkanyl or alkenyl. Preferred alkoxy radicals are methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy and octoxy, where each of these radicals can also be substituted, namely preferably by one or more fluorine atoms. Particularly preferably, alkoxy is —OCH3, —OC2H5, —O-n-C3H7, —O-n-C4H9, —O-t-C4H9, —OCF3, —OCHF2, —OCHF or —OCHFCHF2. In connection with the present invention, the expression “oxaalkyl” denotes alkyl radicals in which at least one nonterminal CH2 group is replaced by —O— such that no adjacent heteroatoms (O, S) are present. Preferably, oxaalkyl comprises straight-chain radicals of the formula CaH2a+1—O—(CH2)b—, where a and b in each case independently of one another are 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; particularly preferably, a is an integer from 1 to 6 and b is 1 or 2.


If, in an alkyl radical as defined above, one or more CH2 groups are replaced by sulfur, a “thioalkyl” radical is present. Preferably, “thioalkyl” comprises a straight-chain radical of the formula CaH2a+1—S—(CH2)b—, where a is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 and b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; particularly preferably, a is an integer from 1 to 6 and b is 0, 1 or 2. The thioalkyl radical can likewise be substituted by F, Cl, Br, I and/or —CN and is preferably unsubstituted.


In the context of the present invention, the expression “alkenyl” is an alkyl radical as defined as above, in which one or more —CH═CH— groups are present. If two —CH═CH— groups are present in the radical, this can also be designated as “alkadienyl”. An alkenyl radical can contain 2 to 15 (i.e. 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15) carbon atoms and is branched-chain or preferably straight-chain. The radical is unsubstituted or mono- or polysubstituted identically or differently, in particular by F, Cl, Br, I and/or —CN, i.e. one or both hydrogens of the —CH═CH— unit and/or one or more hydrogens of the further CH2 or CH3 groups of the alkenyl radical can be replaced by the corresponding substituent(s). Furthermore, one or more CH2 groups can in each case independently of one another be substituted by —O—, —S—, —C≡C—, —CO—, —CO—O— or —O—CO— such that heteroatoms (O, S) are not linked directly to one another. Alkenyl radicals in which one CH2 group is replaced by —O— is also designated here as “alkenyloxy”. If the CH═CH group carries a radical other than hydrogen on both carbon atoms, for example if it is a nonterminal group, the CH═CH group can be present in two configurations, namely as the E isomer and as the Z isomer. The same applies for the double bond groups substituted by halogen and/or —CN. In general, the E isomer (trans) is preferred. Preferably, the alkenyl radical contains 2, 3, 4, 5, 6 or 7 carbon atoms and is vinyl, allyl, 1E-propenyl, 2-propenyl, 1E-butenyl, 1E-pentenyl, 1E-hexenyl, 1E-heptenyl, 2-propenyl, 2E-butenyl, 2E-pentenyl, 2E-hexenyl, 2E-heptenyl, 3-butenyl, 3E-pentenyl, 3E-hexenyl, 3E-heptenyl, 4-pentenyl, 4Z-hexenyl, 4E-hexenyl, 4Z-heptenyl, 5-hexenyl and 6-heptenyl, Particularly preferred alkenyl radicals are vinyl, allyl, 1E-propenyl, 2-propenyl and 3E-butenyl.


If, in an alkyl radical, one or more CH2 groups are replaced by —C≡C—, an alkynyl radical is present. The replacement of one or more CH2 groups by —CO—O— or —O—CO— is also possible. The following of these radicals are preferred here: acetyloxy, propionyloxy, butyryl-oxy, pentanoyloxy, hexanoyloxy, acetyloxymethyl, propionyloxymethyl, butyryloxymethyl, pentanoyloxy-methyl, 2-acetyloxyethyl, 2-propionyloxyethyl, 2-butyryloxyethyl, 2-acetyloxypropyl, 3-propionyloxy-propyl, 4-acetyloxybutyl, methoxycarbonyl, ethoxy-carbonyl, propoxycarbonyl, butoxycarbonyl, pentoxy-carbonyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl, butoxycarbonylmethyl, 2-(methoxycarbonyl)ethyl, 2-(ethoxycarbonyl)ethyl, 2-(propoxycarbonyl)ethyl, 3-(methoxycarbonyl)propyl, 3-(ethoxycarbonyl)propyl or 4-(methoxycarbonyl)butyl.


If, in an alkyl radical, a CH2 group is replaced by unsubstituted or substituted —CH═CH— and an adjacent CH2 group is replaced by CO, CO—C— or O—CO—, this radical can be straight-chain or branched. Preferably, it is straight-chain and has 4 to 12 C atoms. Accordingly, it is particularly preferably acryloyloxymethyl, 2-acryloyloxyethyl, 3-acryloyloxypropyl, 4-acryloyloxybutyl, 5-acryloyloxypentyl, 6-acryloyloxyhexyl, 7-acryloyloxyheptyl, 8-acryloyloxyoctyl, 9-acryloyloxynonyl, methacryloyloxymethyl, 2-methacryloyloxyethyl, 3-methacryloyloxypropyl, 4-methacryloyloxybutyl, 5-methacryloyloxypentyl, 6-methacryloyloxyhexyl, 7-methacryloyloxyheptyl or 8-methacryloyloxyoctyl.


If the alkyl radical, alkanyl radical, alkenyl radical or alkoxy radical is substituted by at least one halogen, this radical is preferably straight-chain. Halogen is preferably F or Cl. In the case of poly-substitution, halogen is preferably F. The resulting radicals also include perfluorinated radicals. In the case of monosubstitution, the fluorine or chlorine substituent can be in any desired position, but preferably in the ω position.


In connection with the present invention, the expression “fluoroalkyl” designates an alkyl radical as defined above, which is substituted by one or more fluorine atoms. Preferably, the fluoroalkyl radical has 1 to 7 carbon atoms. Particularly preferred fluoro alkyl radicals are, in addition to CF3 and CHF2, highly fluorinated alkyl radicals such as C2F5, CHFCF3 and CHFCHF2.


In connection with the present invention, the expression “fluoroalkoxyl” designates an alkoxy radical as defined above, which is substituted by one or more fluorine atoms. Preferably, the fluoroalkoxy radical has 1 to 7 carbon atoms. Particularly preferred fluoro-alkoxy radicals are, in addition to OCF3, OCHF2 and OCH2F, highly fluorinated alkoxy radicals such as OC2F5, OCHFCF3 and OCHFCHF2.


In the context of the present invention, the expression “aryl”—if it is not defined differently in the individual cases in another position in the description or in the claims—means an aromatic hydrocarbon having 6 to 14 carbon atoms, which is optionally mono- or polysubstituted by halogen, nitro, alkanyl, alkoxy, —NH2 or by —N(alkanyl)2, where the polysubstitution can take place with the same or with different substituents. The expression also comprises aromatic hydrocarbons having more than one ring, i.e. fused ring systems and ring systems having rings linked via single or double bonds. In particular, “aryl” is an unsubstituted or substituted phenyl, naphthyl or 4,4′-biphenyl radical.


In connection with the present invention, the expression “aralkyl” represents an arylalkyl radical, i.e. a radical in which an aryl substituent is linked to an atom, a chain, another radical or a functional group via an alkyl bridge. The alkyl bridge is preferably a saturated bivalent hydrocarbon radical (“alkylene”), in particular methylene (—CH2—) and ethylene (—CH2—CH2—). Preferred examples of an aralkyl radical are benzyl and phenethyl. For the purposes of the present invention, an “aralkyl-O— radical” is an aralkyl radical which is linked to a further atom, a chain, another radical or a functional group via an oxygen atom bonded to the alkyl bridge. Preferred examples of an aralkyl-O— radical are O-benzyl and O—CH2CH2phenyl.


In the context of the present invention, “alkylenel” or “alkylene bridge”—if the terms are not defined differently in another position in this description or in the claims—represents a bivalent aliphatic hydrocarbon radical having 1, 2, 3, 4, 5, 6, 7, 8 carbon atoms in the chain, which can optionally also be mono- or polysubstituted by halogen, CN, carboxyl, nitro, alkanyl, alkoxy, —NH2 or by —N(alkanyl)2, where the polysubstitution can take place by the same or by different substituents. Preferably, “alkylene” or “alkylene bridge” represents a straight-chain, saturated aliphatic radical having 1, 2, 3, 4, 5, 6 carbon atoms, which is unsubstituted or mono- or disubstituted by methyl, in particular —CH2—CH2—, —CH2—CH2—CH2—, —(CH2)4— and —CH2C(CH3)2CH2—.


If radicals or substituents of the compounds according to the invention or the compounds according to the invention themselves are present as optically active or stereoisomeric radicals, substituents or compounds because they have, for example, an asymmetric center, these are additionally comprised by the present invention. It is obvious here that the compounds of the general formula I according to the invention can be present in isomerically pure form, for example as pure enantiomers, diastereomers, E or Z isomers, trans or cis isomers, or as a mixture of a number of isomers in any desired ratio, for example as a racemate, E/Z isomer mixture or as a cis/trans isomer mixture.


For the protection of optionally reactive functional groups or substituents optionally contained in the molecule from undesired reactions in the reaction according to the invention and/or preceding or subsequent reaction and/or workup steps, protective groups can be employed which are removed again after reaction has taken place. Methods for the use of suitable protective groups are known to the person skilled in the art and described, for example, in T. W. Green, P. G. M. Wuts: Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons (1999).







EXAMPLES

The starting substances can be obtained according to generally accessible literature procedures or commercially. The reactions described are known from the literature. In addition to the customary and wells known abbreviations, the following abbreviations are used:

  • C: Crystalline phase; N: Nematic phase; I: Isotropic phase.


Temperatures, if not stated otherwise, are in ° C.


The determination of physical, physicochemical or electrooptical parameters is carried out according to generally known methods, such as are described, inter alia, in the booklet “Merck Liquid Crystals—Licristal®—Physical Properties of Liquid Crystals—Description of the Measurements Methods”, 1998, Merck KGaA, Darmstadt.


The dielectric anisotropy Δ∈ is determined at 20° C. and 1 kHz. The optical anisotropy Δn is determined at 20° C. and a wavelength of 589.3 nm.


Example A
a) Preparation of 3-heptyl-3,4-dihydrochromen-2-one (6)

The preparation is carried out—as shown in the reaction scheme below—according to Houben-Weyl, Methoden der Organischen Chemie, Georg Thieme Verlag, Stuttgart, N.Y., 4th ed., 1993.




embedded image


Here, the salicylaldehyde 1 is reacted under basic catalysis with diethyl malonate 2 to give the benzo-chromene 3. Hydrogenation under heterogeneous catalysis affords the corresponding benzochroman derivative 4, which is converted into 5 with n-heptyl iodide under basic catalysis. Hydrolysis and decarboxylation finally afford the lactone 6.)


b) Preparation of 15-heptyl-7-oxa-1,5-dithia-[8,13]-enzospiro[5.5]undecane (7)



embedded image



29 ml (58 mmol) of a 2 M solution of trimethylaluminum in heptane are initially introduced into 50 ml of dichloromethane under nitrogen, cooled to −75° C., and a solution of 2.9 ml (28.9 mmol) of 1,3-propanedithiol in 15 ml of dichloromethane is added dropwise. The mixture is allowed to thaw and is cooled to −20° C., and a solution of 6.80 g (27.6 mmol) of 3-heptyl-3,4-dihydrochromen-2-one (6) in 35 ml of dichloromethane is added dropwise. The mixture is stirred at room temperature overnight, added to ice water and extracted with dichloromethane. The combined organic phases are washed with water and dried over sodium sulfate. The solvent is removed in vacuo, and the residue is filtered through silica gel using heptane/methyl tert-butyl ether (MTBE) (8:2). 7.20 g (79%) of dithio-orthoester 7 are obtained as a yellow oil, which is employed in the next stage without further purification.


c) 2,2-Difluoro-3-heptyl-3,4-dihydro-2H-chromene (8)



embedded image



7.20 g (21.4 mmol) of dithioorthoester 7 and 17.5 ml (109 mmol) of triethylamine tris(hydrofluoride) are initially introduced at −70° C. into 120 ml of dichloromethane and subsequently treated in portions with a suspension of 31.0 g (109 mmol) of DBH in 80 ml of dichloromethane. After 2 h, the mixture is warmed to −30° C. and the orange-colored suspension is then added to a mixture of 44 ml of sodium hydrogensulfite solution and 400 ml of ice-cold 2 N sodium hydroxide solution. The aqueous phase is separated off and extracted twice with dichloromethane. The combined organic phases are washed with water, dried over sodium sulfate and purified by chromatography on silica gel. 1.7 g (30%) of 2,2-difluoro-3-heptyl-3,4-dihydro-2H-chromene (8) are obtained as a colorless liquid.



19F-NMR (282 MHz, CDCl3) δ=−74.0 ppm (ddd, 3JF,H=2.2 Hz, 3JF,H=3.8 Hz, 2JF,F=154 Hz, 1 F, CF2O), −79.1 (ddd, 3JF,H=3.0 Hz, 3JF,H=13.0 Hz, 2JF,F=154 Hz, 1 F, CF2O).


Example B
a) 3-Fluoro-4-butoxy-2-hydroxybenzaldehyde (11)



embedded image



21.0 g (59.3 mmol) of 1-bromo-4-butoxy-3-fluoro-2-(2-methoxyethoxymethoxy)benzene (9) are dissolved in 200 ml of THF and treated at −78° C. with 37 ml (60 mmol) of a 15% strength solution of n-butyllithium in hexane. After 1 h, 6.8 ml (61 mmol) of N-formylpiperidine are added dropwise in 50 mmol of THF. The mixture is subsequently stirred for 1 h, and the mixture is allowed to thaw. After hydrolysis, the solution is acidified and extracted with MTBE. The combined organic phases are washed with water and dried over sodium sulfate. The solvent is removed in vacuo, the residue is taken up in 150 ml of THF, and after addition of 30 ml of conc. hydrochloric acid the mixture is stirred at room temperature overnight. The mixture is taken up in MTBE and washed with water (pH 5). The solvent is removed in vacuo and the crude product is filtered through silica gel using MTBE. 8.80 g (53%, 2 stages) of 3-fluoro-4-butoxy-2-hydroxybenzaldehyde (11) are obtained as a slightly violet solid.


b) 7-Butoxy-8-fluoro-3-[4-(4-trans-pentylcyclohexyl)-phenyl]chromen-2-one (13)



embedded image



8.60 g (37.4 mmol) of 3-fluoro-4-butoxy-2-hydroxybenzaldehyde (11), 10.7 g (37.1 mmol) of 4-trans-pentyl-(4-cyclohexylphenyl)acetic acid (12), 5.2 ml (37.4 mmol) of triethylamine and 18 ml (190 mmol) of acetic anhydride are heated under reflux for 24 h. The solution is added to water, extracted with MTBE, and the combined organic phases are washed with water and dried over sodium sulfate. The solvent is removed in vacuo and the residue is recrystallized from acetonitrile. 10.8 g (57%) of 7-butoxy-8-fluoro-3-[4-(4-trans-pentyl-cyclohexyl)phenyl]chromen-2-one (13) are obtained as colorless crystals.


c) 7-Butoxy-8-fluoro-3-[4-(4-trans-pentylcyclohexyl)-phenyl]chroman-2-one (14)



embedded image



16.7 g of 7-butoxy-8-fluoro-3-[4-(4-trans-pentylcyclo-hexyl)phenyl]chromen-2-one (13) are hydrogenated to completion on palladium-active carbon catalyst in tetrahydrofuran. The solution is filtered and concentrated, and the residue is filtered through silica gel using toluene/heptane (2:1). 12.2 g (77%) of 7-butoxy-8-fluoro-3-[4-(4-trans-pentylcyclohexyl)phenyl]-chroman-2-one (14) are obtained as colorless crystals of melting point 145° C.


MS (EI) m/e (%)=466 [M+] (100), 438 [M+-CO] (74), 382 [M+-CO-Bu] (84).



1H-NMR (300 MHz, CDCl3) δ=0.83-1.59 ppm (m, 22H), 1.73-1.94 (m, 5H), 2.45 (tt, 3J=3.0 Hz, 3J=11.5 Hz, 1H, Ar—CH(CH2)2, 3.18 (AB-dd, 3J=6.5 Hz, 3J=16.0 Hz, 1H, Ar—CH2—CH), 3.30 (AB-dd, 3J=10.5 Hz, 3J=16.0 Hz, 1H, Ar—CH2—CH), 3.94 (dd, 3J=6.5 Hz, 3J=10.5 Hz, 1H, ArCHC(O)O—Ar), 4.03 (t, 3J=6.6 Hz, 2H, Ar—OCH2C3H7), 6.70 (mc, 1H, Ar—H), 6.83 (mc, 1H, Ar—H), 7.17 (mc, 4H, Ar—H).


d) 9-Fluoro-10-butoxy-15-(4-trans-pentyl(4-cyclohexyl-phenyl))-7-oxa-1,5-dithia[8,13]benzospiro[5.5]undecane (15)



embedded image


In analogy to the synthesis described above in Example A b), starting from 10.1 g of 7-butoxy-8-fluoro-3-[4-(4-trans-pentylcyclohexyl)phenyl]chroman-2-one (14), 8.7 g (70%) of 9-fluoro-10-butoxy-15-(4-trans-pentyl-(4-cyclohexylphenyl))-7-oxa-1,5-dithia[8,13]benzospiro-[5.5]undecane (15) are obtained as a colorless solid.


MS (EI) m/e (%)=556 [M+] (100) 460 (87).


e) 7-Butoxy-2,2,8-trifluoro-3-[4-(4-trans-pentyl cyclohexyl)phenyl]chroman (16)



embedded image


In analogy to the synthesis described in example A c), starting from 4.60 g of 9-fluoro-10-butoxy-15-(4-trans-pentyl(4-cyclohexylphenyl))-7-oxa-1,5-dithia[8,13]-benzo-spiro[5.5]undecane (15), 2.40 g (61%) of 7-butoxy-2,2,8-trifluoro-3-[4-(4-trans-pentylcyclohexyl)phenyl]-chroman (16) are obtained as a colorless solid.


Phase behavior: C 76 N 89.6 I. Δ∈=−9.3; Δn=0.1232.



19F-NMR (282 MHz, CDCl3) δ=−75.6 ppm (ddd, 3JF,H=2.2 Hz, 3JF,H=4.4 Hz, 2JF,F=153 Hz, 1 F, CF2O), −79.1 (dd, 3JF,H=18.8 Hz, 2JF,F=153 Hz, 1 F, CF2O).


MS (EI) m/e (%)=488 [M+] (100), 432 [M+-Bu] (52).


Example C
a) 3-Fluoro-2-benzyloxy-4-butoxybenzaldehyde (18)



embedded image


In analogy to the reaction of 9 to 10 in Example B a) above, starting from 61.6 g (0.189 mol) of 1-bromo-2-benzyloxy-4-butoxy-3-fluorobenzene (17), 37.5 g (70%) of 3-fluoro-2-benzyloxy-4-butoxybenzaldehyde (18) are obtained as yellow crystals.


b) Methyl 3-(2-(benzyloxy)-4-ethoxy-3-fluorophenyl)-3-hydroxy-2-(4-trans-propylcyclohexyl)propionate (20)



embedded image



21 ml (0.149 mol) of diisopropylamine are dissolved in 300 ml of THF and 94 ml (0.149 mol) of a 15% solution of n-butyllithium in hexane are added at −78° C. The mixture is allowed to thaw and is cooled again to −78° C. Subsequently, 30.0 g (0.149 mol) of methyl (4-trans-propylcyclohexyl)acetate (19) in 300 ml of THF are added dropwise. After 2 h, a solution of 42.1 g (0.149 mol) of 3-fluoro-2-benzyloxy-4-ethoxybenzaldehyde (18) in 300 ml of THF is added dropwise, and the mixture is stirred for 2 h and warmed to −5° C. After hydrolysis, the solution is slightly acidified and extracted three times with MTBE. The combined organic phases are washed with water, the solvent is removed in vacuo and the residue is filtered through silica gel using heptane/MTBE (7:3). 51.3 g (72%) of methyl 3-(2-(benzyloxy)-4-ethoxy-3-fluorophenyl)-3-hydroxy-2-(4-transpropylcyclohexyl)propionate (20) are obtained as a viscous yellow oil.


MS (EI) m/e (%)=455 [M+-OH] (2), 275 (70), 91 [C7H7+] (100).



1H-NMR (300 MHz, CDCl3) δ=0.72-1.90 ppm (m, 20H), 2.64 (d, 3J=6.2 Hz, 1H, OH), 2.82 (dd, 3J=4.1 Hz, 3J=8.2 Hz, 1H, CHCOOMe), 3.47 (s, 3H, OCH3), 4.10 (q, 3J=7.0 Hz, —OCH2CH3), 4.99 (dd, 3J=6.2 Hz, 3J=8.2 Hz, 1H, Ar—CH(OH)—), 5.11 (d, 3J=10.9 Hz, 1H, PhCH2O—), 5.27 (d, 3J=11.4 Hz, 1H, PhCH2O—), 6.64 (t, 3J=8.2 Hz, 1H, Ar—H), 6.97 (dd, 3J=1.8 Hz, 3J=8.6 Hz, 1H, Ar—H), 7.42 (mc, 5H, Ar—H).


c) Methyl 3-(2-(benzyloxy)-4-ethoxy-3-fluorophenyl)-2-(4-trans-propylcyclohexyl)acrylate (21)



embedded image



50.0 g (0.106 mol) of methyl 3-(2-(benzyloxy)-4-ethoxy-3-fluorophenyl)-3-hydroxy-2-(4-trans-propylcyclohexyl)-propionate (20) are dissolved in 500 ml of dichloro-methane and, after addition of 44 ml (0.317 mol) of triethylamine and 240 mg of N,N-dimethylaminopyridine, treated with 9.0 ml (116 mmol) of mesyl chloride with ice cooling. Subsequently, the cooling is removed and the mixture is heated under reflux for 1 h. The solution is washed three times with water and dried over sodium sulfate. The solvent is removed in vacuo and the residue is filtered through silica gel using heptane/MTB ether (8:2). 31.6 g (56%) of methyl 3-(2-(benzyloxy)-4-ethoxy-3-fluorophenyl)-2-(4-trans-propylcyclohexyl)acrylate (21) are obtained as a yellow oil.


d) Methyl 3-(4-ethoxy-3-fluoro-2-hydroxyphenyl)-2-(4-trans-propylcyclohexyl)propionate (22)



embedded image



7.60 g of methyl 3-(2-(benzyloxy)-4-ethoxy-3-fluoro-phenyl)-2-(4-trans-propylcyclohexyl)acrylate (21) are hydrogenated to completion in THF on palladium-active carbon catalyst (5%). The solvent is removed in vacuo and the residue is filtered through silica gel using heptane/MTBE (8:2). 4.60 g (76%) of methyl 3-(4-ethoxy-3-fluoro-2-hydroxyphenyl)-2-(4-trans-propylcyclohexyl)-propionate (22) are obtained as colorless crystals.


e) 7-Ethoxy-8-fluoro-3-(4-trans-propylcyclohexyl)-chroman-2-one (23)



embedded image



14.5 g (37.3 mmol) of methyl 3-(4-ethoxy-3-fluoro-2-hydroxyphenyl)-2-(4-trans-propylcyclohexyl)propionate (22) are dissolved in 60 ml of diphenyl ether and heated under reflux for 2 h. The mixture is added to 100 g of silica gel and the diphenyl ether is eluted using heptane. Subsequently, by diluting with heptane/MTBE (9:1), 9.10 g (72%) of 7-ethoxy-8-fluoro-3-(4-trans-propylcyclohexyl)chroman-2-one (23) are obtained as colorless flakes.


MS (EI) m/e (%)=334 [M+] (84), 170 (100).



1H-NMR (300 MHz, CDCl3) δ=0.78-1.35 (m, 12H), 1.44 (t, 3J=7.1 Hz, 3H, CH3), 1.65-1.85 (m, 5H), 2.54 (mc, 1H, CH), 2.87 (AB-dd, 3J=8.3 Hz, 2J=15.9 Hz, 1H, ArCH2), 2.95 (AB-dd, 3J=6.5 Hz, 2J=15.9 Hz, 1H, Ar—CH2—), 4.10 (q, 3J=7.0 Hz, 2H, CH3CH2O—), 6.66 (dd, 3J=7.27 Hz, 1H, Ar—H), 6.81 (mc, 1H, Ar—H3).


f) 10-Ethoxy-9-fluoro-15-(4-trans-propylcyclohexyl)-7-oxa-1,5-dithia[8,13]benzospiro[5.5]undecane (24)



embedded image


In analogy to the synthesis described in Example A b), starting from 9.10 g (26.9 mmol) of 7-ethoxy-8-fluoro-3-(4-trans-propylcyclohexyl)chroman-2-one (23), 5.60 g (49%) of 10-ethoxy-9-fluoro-15-(4-trans-propylcyclo-hexyl)-7-oxa-1,5-dithia[8,13]benzospiro[5.5]undecane (24) are obtained as a colorless solid.


MS (EI) m/e (%)=424 [M+] (100), 256 (70).


g) 7-Ethoxy-2,2,8-trifluoro-3-(4-trans-propylcyclo hexyl)chroman (25)



embedded image


In analogy to the synthesis described in Example A c) starting front 5.60 g (13.2 mmol) of 10-ethoxy-9-fluoro-15-(4-trans-propylcyclohexyl)-7-oxa-1,5-dithia[8,13]-benzospiro[5.5]undecane (24), 1.80 g (38%) of 7-ethoxy-2,2,8-trifluoro-3-(4-trans-propylcyclohexyl)chroman (25) are obtained as a colorless solid.


Phase behavior C 81 N (−6) I. Δ∈=−11.1; Δn=0.0728.


MS (EI) m/e (%)=356 [M+] (100), 328 [M+-C2H5] (45).



1H-NMR (250 MHz, CDCl3) δ=0.80-1.37 ppm (m, 12H), 1.42 (t, 3J=7.0 Hz, 3H, CH3), 1.80 (mc, 5H) 2.40 (mc, 1H, Ar—CH2—), 2.84 (mc, 2H, Ar—CH2— and —CHCF2O) 4.09 (q, 3J=7.0 Hz, 2H, OCH2CH3), 6.61 (dd, 3J=6.4 Hz, 3J=8.5 Hz, 1H, Ar—H), 6.67 (mc, 1H, Ar—H).



19F-NMR (235 MHz, CDCl3) δ=−74.0 ppm (dd, 3JF,H=2.6 Hz, 2JF,F=152 Hz, 1 F, CF2O), −75.9 (dd, 3JF,H=19.2 Hz, 2JF,F=152 Hz, 1 F, CF2O), −157 (dd, 3JF,H=1.5 Hz, 3JF,H=7.2 Hz, 1 F, Ar—F).


Example D
a1) 6-Oxa-1,4-dithia[7,8]benzospiro[4.5]decane (27)



embedded image



236 ml (0.472 mol) of a 2 M solution of trimethyl-aluminum in heptane are initially introduced at −78° C., and a solution of 19.9 ml (0.236 mol) of ethanedithiol in 20 ml of dichloromethane is added. The mixture is allowed to thaw and is cooled to −20° C. and a solution of 35.0 g (0.236 mol) of dihydrocoumarin (26) in 330 ml of dichloromethane is added dropwise. The mixture is stirred overnight at room temperature, ice is added and it is acidified with conc. hydrochloric acid. The aqueous phase is separated off and extracted with dichloromethane. The combined organic phases are washed with water, dried over sodium sulfate and concentrated. After filtration of the crude product using heptane/MTB ether (2:1) on silica gel, 44.5 g (84%) of dithio-orthoester 27 are obtained as a colorless oil.


MS (EI): m/e (%)=223 (100) [M+-H].



1H-NMR (300 MHz, CDCl3) δ=2.62 ppm (t, 3J=6.7 Hz, 2H, ArCH2CH2), 3.02 (t, 3J=6.7 Hz, 2H, ArCH2CH2), 3.53 (mc, 4H, —SCH2CH2S—), 6.87 (mc, 2H, Ar—H), 7.11 (mc, 2H, Ar—H).


a2) 7-Oxa-1,5-dithia[8,9]benzospiro[5.5]undecane (31)



embedded image



10 g (55.5 mmol) of o-methoxyphenylpropionic acid (29) and 6.1 ml of 1,3-propanedithiol are initially introduced and, after addition of 14.6 ml (0.167 mol) of trifluoromethanesulfonic acid, heated at 120° C. for 2 h. The reaction mixture is added to sodium hydroxide solution with cooling, extracted with toluene, and the combined organic phases are dried over sodium sulfate. The solvent is removed in vacuo and the residue is filtered through silica gel using 1-chlorobutane. 6.48 g (49%) of spiro compound 31 are obtained as a yellow oil.


MS (EI) m/e (%)=238 (100) [M+].



1H-NMR (300 MHz, CDCl3) δ=2.07 ppm (mc, 1H, —SCH2CH2CH2S—) 2.25 (mc, 1H, —SCH2C1H2CH2S—) 2.32 (t, J=7.0 Hz, 2H, Ar—CH2CH2—), 2.71 (dt, J=14.4 Hz, J=3.4 Hz, 2H, —SCH2CH2CH2S—), 2.97 (t, J=7.0 Hz, 2H, Ar—CH2—CH2), 3.64 (mc, 2H, —SCH2CH2CH2S—), 6.92 (mc, 2H, Ar—H), 7.08 (d, J=7.6 Hz, 1H, Ar—H), 7.13 (mc, therein: t, J=7.6 Hz, 1H, Ar—H).


B) 2,2-Difluorochroman (32)



embedded image



5.00 g (22.3 mmol) of dithioorthoester 27 are dissolved in 120 ml of dichloromethane and first treated with 18 ml (0.111 mol) of triethylamine trishydrofluoride at −75° C. Subsequently, a suspension of 31.9 g (0.111 mol) of 1,3-dibromo-5,5-dimethylhydantoin are added in portions in 50 ml of dichloromethane in the course of 30 min. The mixture is stirred for a further 2.5 h, warmed to room temperature, hydrolyzed using 1 N sodium hydroxide solution and extracted three times with dichloromethane. The combined organic phases are dried over sodium sulfate, concentrated and the crude product is filtered through silica gel using n-heptane/ethyl acetate (50:1). The product is further purified by bulb tube distillation. 2.80 g (74%) of the target compound 32, a slightly yellow liquid, are obtained, Content: 99.2% (GC).


Analogously, 32 can also be prepared from compound 31 (Example D a2)).



1H-NMR (300 MHz, CDCl3) δ=2.32 ppm (tt, 3JF,H=8.9 Hz, 3JH,H=7.1 Hz, 2H, CH2), 2.96 (t, 3JH,H=7.1 Hz, 2H, CH2), 6.99 (mc, 2H, Ar—H), 7.18 (mc, 2H, Ar—H).



13C-NMR (75 MHz, CDCl3)=δ=22.54 (t, 3JC,F=4.0 Hz, CH2CH2CF2), 27.88 (t, 2JC,F=29.1 Hz, CH2CH2CF2), 116.85 (CH), 120.47 (C) 123.03 (CH)/123.16 (t, 1JC,F=255 Hz, CF2O), 128.15 (CH), 128.78 (CH), 150.95 (C).



19F-NMR (282 MHz, CDCl3) δ=−69.77 ppm (t, 3JF,H=8.9 Hz, 2 F, CF2).


MS (EI) m/e (%)=170 (100) [M+], 150 (7) [M+-HF].


HR-MS (EI) calc.: m/e=170.054716; fnd: m/e 170.054321.


Example E



embedded image


Analogously to Example D, starting from (2-methoxyphenyl)acetic acid (33), 2,2-difluoro-2,3-dihydrobenzofuran (36) is obtained as a colorless liquid.



1H-NMR (300 MHz, CDCl3) δ=3.59 ppm (t, 3JF,H=14.0 Hz, 2H, CH2), 6.96 (d, J=8.1 Hz, 1H, Ar—H), 7.04 (dd, J=0.9 Hz, J=7.5 Hz, 1H, Ar—H), 7.22 (mc, 2H, Ar—H).



19F-NMR (235 MHz, CDCl3) δ=−63.94 ppm (t, 3JF,H=14.0 Hz, 2 F, CF2)


MS (EI) m/e (%)=156 (100) [M+], 136 (6) [M+-HF].


The following compounds according to the invention are prepared in analogy to the examples A-E described above.


The following are prepared analogously to Example A:


Example 1-105



embedded image


Example 106-210



embedded image


Example 316-420



embedded image














embedded image

















Example No.

R1
R2
















 1,
106,
211,
316
H
CH3


 2,
107,
212,
317
H
C2H5


 3,
108,
213,
318
H
n-C3H7


 4,
109,
214,
319
H
n-C4H9


 5,
110,
215,
320
H
n-C5H11


 6,
111,
216,
321
H
n-C6H13


 7,
112,
217,
322
H
n-C7H15


 8,
113,
218,
323
CH3
CH3


 9,
114,
219,
324
CH3
C2H5


10,
115,
220,
325
CH3
n-C3H7


11,
116,
221,
326
CH3
n-C4H9


12,
117,
222,
327
CH3
n-C5H11


13,
118,
223,
328
CH3
n-C6H13


14,
119,
224,
329
CH3
n-C7H15


15,
120,
225,
330
C2H5
CH3


16,
121,
226,
331
C2H5
C2H5


17,
122,
227,
332
C2H5
n-C3H7


18,
123,
228,
333
C2H5
n-C4H9


19,
124,
229,
334
C2H5
n-C5H11


20,
125,
230,
335
C2H5
n-C6H13


21,
126,
231,
336
C2H5
n-C7H15


22,
127,
232,
337
n-C3H7
CH3


23,
128,
233,
338
n-C3H7
C2H5


24,
129,
234,
339
n-C3H7
n-C3H7


25,
130,
235,
340
n-C3H7
n-C4H9


26,
131,
236,
341
n-C3H7
n-C5H11


27,
132,
237,
342
n-C3H7
n-C6H13


28,
133,
238,
343
n-C3H7
n-C7H15


29,
134,
239,
344
n-C4H9
CH3


30,
135,
240,
345
n-C4H9
C2H5


31,
136,
241,
346
n-C4H9
n-C3H7


32,
137,
242,
347
n-C4H9
n-C4H9


33,
138,
243,
348
n-C4H9
n-C5H11


34,
139,
244,
349
n-C4H9
n-C6H13


35,
140,
245,
350
n-C4H9
n-C7H15


36,
141,
246,
351
n-C5H11
CH3


37,
142,
247,
352
n-C5H11
C2H5


38,
143,
248,
353
n-C5H11
n-C3H7


39,
144,
249,
354
n-C5H11
n-C4H9


40,
145,
250,
355
n-C5H11
n-C5H11


41,
146,
251,
356
n-C5H11
n-C6H13


42,
147,
252,
357
n-C5H11
n-C7H15


43,
148,
253,
358
n-C6H13
CH3


44,
149,
254,
359
n-C6H13
C2H5


45,
150,
255,
360
n-C6H13
n-C3H7


46,
151,
256,
361
n-C6H13
n-C4H9


47,
152,
257,
362
n-C6H13
n-C5H11


48,
153,
258,
363
n-C6H13
n-C6H13


49,
154,
259,
364
n-C6H13
n-C7H15


50,
155,
260,
365
n-C7H15
CH3


51,
156,
261,
366
n-C7H15
C2H5


52,
157,
262,
367
n-C7H15
n-C3H7


53,
158,
263,
368
n-C7H15
n-C4H9


54,
159,
264,
369
n-C7H15
n-C5H11


55,
160,
265,
370
n-C7H15
n-C6H13


56,
161,
266,
371
n-C7H15
n-C7H15


57,
162,
267,
372
OCH3
CH3


58,
163,
268,
373
OCH3
C2H5


59,
164,
269,
374
OCH3
n-C3H7


60,
165,
270,
375
OCH3
n-C4H9


61,
166,
271,
376
OCH3
n-C5H11


62,
167,
272,
377
OCH3
n-C6H13


63,
168,
273,
378
OCH3
n-C7H15


64,
169,
274,
379
OC2H5
CH3


65,
170,
275,
380
OC2H5
C2H5


66,
171,
276,
381
OC2H5
n-C3H7


67,
172,
277,
382
OC2H5
n-C4H9


68,
173,
278,
383
OC2H5
n-C5H11


69,
174,
279,
384
OC2H5
n-C6H13


70,
175,
280,
385
OC2H5
n-C7H15


71,
176,
281,
386
O-n-C3H7
CH3


72,
177,
282,
387
O-n-C3H7
C2H5


73,
178,
283,
388
O-n-C3H7
n-C3H7


74,
179,
284,
389
O-n-C3H7
n-C4H9


75,
180,
285,
390
O-n-C3H7
n-C5H11


76,
181,
286,
391
O-n-C3H7
n-C6H13


77,
182,
287,
392
O-n-C3H7
n-C7H15


78,
183,
288,
393
O-n-C4H9
CH3


79,
184,
289,
394
O-n-C4H9
C2H5


80,
185,
290,
395
O-n-C4H9
n-C3H7


81,
186,
291,
396
O-n-C4H9
n-C4H9


82,
187,
292,
397
O-n-C4H9
n-C5H11


83,
188,
293,
398
O-n-C4H9
n-C6H13


84,
189,
294,
399
O-n-C4H9
n-C7H15


85,
190,
295,
400
O-n-C5H11
CH3


86,
191,
296,
401
O-n-C5H11
C2H5


87,
192,
297,
402
O-n-C5H11
n-C3H7


88,
193,
298,
403
O-n-C5H11
n-C4H9


89,
194,
299,
404
O-n-C5H11
n-C5H11


90,
195,
300,
405
O-n-C5H11
n-C6H13


91,
196,
301,
406
O-n-C5H11
n-C7H15


92,
197,
302,
407
O-n-C6H13
CH3


93,
198,
303,
408
O-n-C6H13
C2H5


94,
199,
304,
409
O-n-C6H13
n-C3H7


95,
200,
305,
410
O-n-C6H13
n-C4H9


96,
201,
306,
411
O-n-C6H13
n-C5H11


97,
202,
307,
412
O-n-C6H13
n-C6H13


98,
203,
308,
413
O-n-C6H13
n-C7H15


99,
204,
309,
414
O-n-C7H15
CH3


100, 
205,
310,
415
O-n-C7H15
C2H5


101, 
206,
311,
416
O-n-C7H15
n-C3H7


102, 
207,
312,
417
O-n-C7H15
n-C4H9


103, 
208,
313,
418
O-n-C7H15
n-C5H11


104, 
209,
314,
419
O-n-C7H15
n-C6H13


105, 
210,
315,
420
O-n-C7H15
n-C7H15









Measurements for selected examples:


Example No. 338



embedded image


Phase behavior: C 108 I. Δ∈=−5.9; Δn=0.099.


The following are prepared analogously to Example A:


Example 421-476



embedded image


Example 477-532













embedded image

















Example No.

R1
R2
















421,
477,
H
CH3



422,
478,
H
C2H5



423,
479,
H
n-C3H7



424,
480,
H
n-C4H9



425,
481,
H
n-C5H11



426,
482,
H
n-C6H13



427,
483,
H
n-C7H15



428,
484,
CH3
CH3



429,
485,
CH3
C2H5



430,
486,
CH3
n-C3H7



431,
487,
CH3
n-C4H9



432,
488,
CH3
n-C5H11



433,
489,
CH3
n-C6H13



434,
490,
CH3
n-C7H15



435,
491,
C2H5
CH3



436,
492,
C2H5
C2H5



437,
493,
C2H5
n-C3H7



438,
494,
C2H5
n-C4H9



439,
495,
C2H5
n-C5H11



440,
496,
C2H5
n-C6H13



441,
497,
C2H5
n-C7H15



442,
498,
n-C3H7
CH3



443,
499,
n-C3H7
C2H5



444,
500,
n-C3H7
n-C3H7



445,
501,
n-C3H7
n-C4H9



446,
502,
n-C3H7
n-C5H11



447,
503,
n-C3H7
n-C6H13



448,
504,
n-C3H7
n-C7H15



449,
505,
n-C4H9
CH3



450,
506,
n-C4H9
C2H5



451,
507,
n-C4H9
n-C3H7



452,
508,
n-C4H9
n-C4H9



453,
509,
n-C4H9
n-C5H11



454,
510,
n-C4H9
n-C6H13



455,
511,
n-C4H9
n-C7H15



456,
512,
n-C5H11
CH3



457,
513,
n-C5H11
C2H5



458,
514,
n-C5H11
n-C3H7



459,
515,
n-C5H11
n-C4H9



460,
516,
n-C5H11
n-C5H11



461,
517,
n-C5H11
n-C6H13



462,
518,
n-C5H11
n-C7H15



463,
519,
n-C6H13
CH3



464,
520,
n-C6H13
C2H5



465,
521,
n-C6H13
n-C3H7



466,
522,
n-C6H13
n-C4H9



467,
523,
n-C6H13
n-C5H11



468,
524,
n-C6H13
n-C6H13



469,
525,
n-C6H13
n-C7H15



470,
526,
n-C7H15
CH3



471,
527,
n-C7H15
C2H5



472,
528,
n-C7H15
n-C3H7



473,
529,
n-C7H15
n-C4H9



474,
530,
n-C7H15
n-C5H11



475,
531,
n-C7H15
n-C6H13



476,
532,
n-C7H15
n-C7H15










Measurements for selected examples:


Example No. 502



embedded image


Phase behavior: C 25 I. Δ∈=−6.6; Δn=0.047.


The following are prepared analogously to Example B:


Example 533-637



embedded image


Example 638-742



embedded image


Example 743-847



embedded image


Example 848-952













embedded image

















Example No.

R1
R2
















533,
638,
743,
848
H
CH3


534,
639,
744,
849
H
C2H5


535,
640,
745,
850
H
n-C3H7


536,
641,
746,
851
H
n-C4H9


537,
642,
747,
852
H
n-C5H11


538,
643,
748,
853
H
n-C6H13


539,
644,
749,
854
H
n-C7H15


540,
645,
750,
855
CH3
CH3


541,
646,
751,
856
CH3
C2H5


542,
647,
752,
857
CH3
n-C3H7


543,
648,
753,
858
CH3
n-C4H9


544,
649,
754,
859
CH3
n-C5H11


545,
650,
755,
860
CH3
n-C6H13


546,
651,
756,
861
CH3
n-C7H15


547,
652,
757,
862
C2H5
CH3


548,
653,
758,
863
C2H5
C2H5


549,
654,
759,
864
C2H5
n-C3H7


550,
655,
760,
865
C2H5
n-C4H9


551,
656,
761,
866
C2H5
n-C5H11


552,
657,
762,
867
C2H5
n-C6H13


553,
658,
763,
868
C2H5
n-C7H15


554,
659,
764,
869
n-C3H7
CH3


555,
660,
765,
870
n-C3H7
C2H5


556,
661,
766,
871
n-C3H7
n-C3H7


557,
662,
767,
872
n-C3H7
n-C4H9


558,
663,
768,
873
n-C3H7
n-C5H11


559,
664,
769,
874
n-C3H7
n-C6H13


560,
665,
770,
875
n-C3H7
n-C7H15


561,
666,
771,
876
n-C4H9
CH3


562,
667,
772,
877
n-C4H9
C2H5


563,
668,
773,
878
n-C4H9
n-C3H7


564,
669,
774,
879
n-C4H9
n-C4H9


565,
670,
775,
880
n-C4H9
n-C5H11


566,
671,
776,
881
n-C4H9
n-C6H13


567,
672,
777,
882
n-C4H9
n-C7H15


568,
673,
778,
883
n-C5H11
CH3


569,
674,
779,
884
n-C5H11
C2H5


570,
675,
780,
885
n-C5H11
n-C3H7


571,
676,
781,
886
n-C5H11
n-C4H9


572,
677,
782,
887
n-C5H11
n-C5H11


573,
678,
783,
888
n-C5H11
n-C6H13


574,
679,
784,
889
n-C5H11
n-C7H15


575,
680,
785,
890
n-C6H13
CH3


576,
681,
786,
891
n-C6H13
C2H5


577,
682,
787,
892
n-C6H13
n-C3H7


578,
683,
788,
893
n-C6H13
n-C4H9


579,
684,
789,
894
n-C6H13
n-C5H11


580,
685,
790,
895
n-C6H13
n-C6H13


581,
686,
791,
896
n-C6H13
n-C7H15


582,
687,
792,
897
n-C7H15
CH3


583,
688,
793,
898
n-C7H15
C2H5


584,
689,
794,
899
n-C7H15
n-C3H7


585,
690,
795,
900
n-C7H15
n-C4H9


586,
691,
796,
901
n-C7H15
n-C5H11


587,
692,
797,
902
n-C7H15
n-C6H13


588,
693,
798,
903
n-C7H15
n-C7H15


589,
694,
799,
904
OCH3
CH3


590,
695,
800,
905
OCH3
C2H5


591,
696,
801,
906
OCH3
n-C3H7


592,
697,
802,
907
OCH3
n-C4H9


593,
698,
803,
908
OCH3
n-C5H11


594,
699,
804,
909
OCH3
n-C6H13


595,
700,
805,
910
OCH3
n-C7H15


596,
701,
806,
911
OC2H5
CH3


597,
702,
807,
912
OC2H5
C2H5


598,
703,
808,
913
OC2H5
n-C3H7


599,
704,
809,
914
OC2H5
n-C4H9


600,
705,
810,
915
OC2H5
n-C5H11


601,
706,
811,
916
OC2H5
n-C6H13


602,
707,
812,
917
OC2H5
n-C7H15


603,
708,
813,
918
O-n-C3H7
CH3


604,
709,
814,
919
O-n-C3H7
C2H5


605,
710,
815,
920
O-n-C3H7
n-C3H7


606,
711,
816,
921
O-n-C3H7
n-C4H9


607,
712,
817,
922
O-n-C3H7
n-C5H11


608,
713,
818,
923
O-n-C3H7
n-C6H13


609,
714,
819,
924
O-n-C3H7
n-C7H15


610,
715,
820,
925
O-n-C4H9
CH3


611,
716,
821,
926
O-n-C4H9
C2H5


612,
717,
822,
927
O-n-C4H9
n-C3H7


613,
718,
823,
928
O-n-C4H9
n-C4H9


614,
719,
824,
929
O-n-C4H9
n-C5H11


615,
720,
825,
930
O-n-C4H9
n-C6H13


616,
721,
826,
931
O-n-C4H9
n-C7H15


617,
722,
827,
932
O-n-C5H11
CH3


618,
723,
828,
933
O-n-C5H11
C2H5


619,
724,
829,
934
O-n-C5H11
n-C3H7


620,
725,
830,
935
O-n-C5H11
n-C4H9


621,
726,
831,
936
O-n-C5H11
n-C5H11


622,
727,
832,
937
O-n-C5H11
n-C6H13


623,
728,
833,
938
O-n-C5H11
n-C7H15


624,
729,
834,
939
O-n-C6H13
CH3


625,
730,
835,
940
O-n-C6H13
C2H5


626,
731,
836,
941
O-n-C6H13
n-C3H7


627,
732,
837,
942
O-n-C6H13
n-C4H9


628,
733,
838,
943
O-n-C6H13
n-C5H11


629,
734,
839,
944
O-n-C6H13
n-C6H13


630,
735,
840,
945
O-n-C6H13
n-C7H15


631,
736,
841,
946
O-n-C7H15
CH3


632,
737,
842,
947
O-n-C7H15
C2H5


633,
738,
843,
948
O-n-C7H15
n-C3H7


634,
739,
844,
949
O-n-C7H15
n-C4H9


635,
740,
845,
950
O-n-C7H15
n-C5H11


636,
741,
846,
951
O-n-C7H15
n-C6H13


637,
742,
847,
952
O-n-C7H15
n-C7H15









The following are prepared analogously to Example C:


Example 953-1057



embedded image


Example 1058-1162



embedded image


Example 1163-1267



embedded image


Example 1268-1372



embedded image


Example 1373-1477













Example No.
R1
R2





















953,
1058,
1163,
1268,
1373
H
CH3


954,
1059,
1164,
1269,
1374
H
C2H5


955,
1060,
1165,
1270,
1375
H
n-C3H7


956,
1061,
1166,
1271,
1376
H
n-C4H9


957,
1062,
1167,
1272,
1377
H
n-C5H11


958,
1063,
1168,
1273,
1378
H
n-C6H13


959,
1064,
1169,
1274,
1379
H
n-C7H15


960,
1065,
1170,
1275,
1380
CH3
CH3


961,
1066,
1171,
1276,
1381
CH3
C2H5


962,
1067,
1172,
1277,
1382
CH3
n-C3H7


963,
1068,
1173,
1278,
1383
CH3
n-C4H9


964,
1069,
1174,
1279,
1384
CH3
n-C5H11


965,
1070,
1175,
1280,
1385
CH3
n-C6H13


966,
1071,
1176,
1281,
1386
CH3
n-C7H15


967,
1072,
1177,
1282,
1387
C2H5
CH3


968,
1073,
1178,
1283,
1388
C2H5
C2H5


969,
1074,
1179,
1284,
1389
C2H5
n-C3H7


970,
1075,
1180,
1285,
1390
C2H5
n-C4H9


971,
1076,
1181,
1286,
1391
C2H5
n-C5H11


972,
1077,
1182,
1287,
1392
C2H5
n-C6H13


973,
1078,
1183,
1288,
1393
C2H5
n-C7H15


974,
1079,
1184,
1289,
1394
n-C3H7
CH3


975,
1080,
1185,
1290,
1395
n-C3H7
C2H5


976,
1081,
1186,
1291,
1396
n-C3H7
n-C3H7


977,
1082,
1187,
1292,
1397
n-C3H7
n-C4H9


978,
1083,
1188,
1293,
1398
n-C3H7
n-C5H11


979,
1084,
1189,
1294,
1399
n-C3H7
n-C6H13


980,
1085,
1190,
1295,
1400
n-C3H7
n-C7H15


981,
1086,
1191,
1296,
1401
n-C4H9
CH3


982,
1087,
1192,
1297,
1402
n-C4H9
C2H5


983,
1088,
1193,
1298,
1403
n-C4H9
n-C3H7


984,
1089,
1194,
1299,
1404
n-C4H9
n-C4H9


985,
1090,
1195,
1300,
1405
n-C4H9
n-C5H11


986,
1091,
1196,
1301,
1406
n-C4H9
n-C6H13


987,
1092,
1197,
1302,
1407
n-C4H9
n-C7H15


988,
1093,
1198,
1303,
1408
n-C5H11
CH3


989,
1094,
1199,
1304,
1409
n-C5H11
C2H5


990,
1095,
1200,
1305,
1410
n-C5H11
n-C3H7


991,
1096,
1201,
1306,
1411
n-C5H11
n-C4H9


992,
1097,
1202,
1307,
1412
n-C5H11
n-C5H11


993,
1098,
1203,
1308,
1413
n-C5H11
n-C6H13


994,
1009,
1204,
1309,
1414
n-C5H11
n-C7H15


995,
1199,
1205,
1310,
1415
n-C6H13
CH3


996,
1101,
1206,
1311,
1416
n-C6H13
C2H5


997,
1102,
1207,
1312,
1417
n-C6H13
n-C3H7


998,
1103,
1208,
1313,
1418
n-C6H13
n-C4H9


999,
1104,
1209,
1314,
1419
n-C6H13
n-C5H11


1000,
1105,
1210,
1315,
1420
n-C6H13
n-C6H13


1001,
1106,
1211,
1316,
1421
n-C6H13
n-C7H15


1002,
1107,
1212,
1317,
1422
n-C7H15
CH3


1003,
1108,
1213,
1318,
1423
n-C7H16
C2H5


1004,
1109,
1214,
1319,
1424
n-C7H15
n-C3H7


1005,
1110,
1215,
1320,
1425
n-C7H15
n-C4H9


1006,
1111,
1216,
1321,
1426
n-C7H15
n-C5H11


1007,
1112,
1217,
1322,
1427
n-C7H15
n-C6H13


1008,
1113,
1218,
1323,
1428
n-C7H15
n-C7H15


1009,
1114,
1219,
1324,
1429
OCH3
CH3


1010,
1115,
1220,
1325,
1430
OCH3
C2H6


1011,
1116,
1221,
1326,
1431
OCH3
n-C3H7


1012,
1117,
1222,
1327,
1432
OCH3
n-C4H9


1013,
1118,
1223,
1328,
1433
OCH3
n-C5H11


1014,
1119,
1224,
1329,
1434
OCH3
n-C6H13


1015,
1120,
1225,
1330,
1435
OCH3
n-C7H15


1016,
1121,
1226,
1331,
1436
OC2H5
CH3


1017,
1122,
1227,
1332,
1437
OC2H5
C2H5


1018,
1123,
1228,
1333,
1438
OC2H5
n-C3H7


1019,
1124,
1229,
1334,
1439
OC2H5
n-C4H9


1020,
1125,
1230,
1335,
1440
OC2H5
n-C5H11


1021,
1126,
1231,
1336,
1441
OC2H5
n-C6H13


1022,
1127,
1232,
1337,
1442
OC2H5
n-C7H15


1023,
1128,
1233,
1338,
1443
O-n-C3H7
CH3


1024,
1129,
1234,
1339,
1444
O-n-C3H7
C2H5


1025,
1130,
1235,
1340,
1445
O-n-C3H7
n-C3H7


1026,
1131,
1236,
1341,
1446
O-n-C3H7
n-C4H9


1027,
1132,
1237,
1342,
1447
O-n-C3H7
n-C5H11


1028,
1133,
1238,
1343,
1448
O-n-C3H7
n-C6H13


1029,
1134,
1239,
1344,
1449
O-n-C3H7
n-C7H15


1030,
1135,
1240,
1345,
1450
O-n-C4H9
CH3


1031,
1136,
1241,
1346,
1451
O-n-C4H9
C2H5


1032,
1137,
1242,
1347,
1452
O-n-C4H9
n-C3H7


1033,
1138,
1243,
1348,
1453
O-n-C4H9
n-C4H9


1034,
1139,
1244,
1349,
1454
O-n-C4H9
n-C5H11


1035,
1140,
1245,
1350,
1455
O-n-C4H9
n-C6H13


1036,
1141,
1246,
1351,
1456
O-n-C4H9
n-C7H15


1037,
1142,
1247,
1352,
1457
O-n-C5H11
CH3


1038,
1143,
1248,
1353,
1458
O-n-C5H11
C2H5


1039,
1144,
1249,
1354,
1459
O-n-C5H11
n-C3H7


1040,
1145,
1250,
1355,
1460
O-n-C5H11
n-C4H9


1041,
1146,
1251,
1356,
1461
O-n-C5H11
n-C5H11


1042,
1147,
1252,
1357,
1462
O-n-C5H11
n-C6H13


1043,
1148,
1253,
1358,
1463
O-n-C5H11
n-C7H15


1044,
1149,
1254,
1359,
1464
O-n-C6H13
CH3


1045,
1150,
1255,
1360,
1465
O-n-C6H13
C2H6


1046,
1151,
1256,
1361,
1466
O-n-C6H13
n-C3H7


1047,
1152,
1257,
1362,
1467
O-n-C6H13
n-C4H9


1048,
1153,
1258,
1363,
1468
O-n-C6H13
n-C5H11


1049,
1154,
1259,
1364,
1469
O-n-C6H13
n-C6H13


1050,
1155,
1260,
1365,
1470
O-n-C6H13
n-C7H15


1051,
1156,
1261,
1366,
1471
O-n-C7H16
CH3


1052,
1157,
1262,
1367,
1472
O-n-C7H15
C2H5


1053,
1158,
1263,
1368,
1473
O-n-C7H16
n-C3H7


1054,
1159,
1264,
1369,
1474
O-n-C7H15
n-C4H9


1055,
1160,
1265,
1370,
1475
O-n-C7H15
n-C5H11


1056,
1161,
1266,
1371,
1476
O-n-C7H15
n-C6H13


1057,
1162,
1267,
1372,
1477
O-n-C7H16
n-C7H15









The following are prepared analogously to Example C:


Example 1478-1533



embedded image


Example 1534-1589













embedded image

















Example No.

R1
R2
















1478,
1534,
H
CH3



1479,
1535,
H
C2H5



1480,
1536,
H
n-C3H7



1481,
1537,
H
n-C4H9



1482,
1538,
H
n-C5H11



1483,
1539,
H
n-C6H13



1484,
1540,
H
n-C7H15



1485,
1541,
CH3
CH3



1486,
1542,
CH3
C2H5



1487,
1543,
CH3
n-C3H7



1488,
1544,
CH3
n-C4H9



1489,
1545,
CH3
n-C5H11



1490,
1546,
CH3
n-C6H13



1491,
1547,
CH3
n-C7H15



1492,
1548,
C2H5
CH3



1493,
1549,
C2H5
C2H5



1494,
1550,
C2H5
n-C3H7



1495,
1551,
C2H5
n-C4H9



1496,
1552,
C2H5
n-C5H11



1497,
1553,
C2H5
n-C6H13



1498,
1554,
C2H5
n-C7H15



1499,
1555,
n-C3H7
CH3



1500,
1556,
n-C3H7
C2H5



1501,
1557,
n-C3H7
n-C3H7



1502,
1558,
n-C3H7
n-C4H9



1503,
1559,
n-C3H7
n-C5H11



1504,
1560,
n-C3H7
n-C6H13



1505,
1561,
n-C3H7
n-C7H15



1506,
1562,
n-C4H9
CH3



1507,
1563,
n-C4H9
C2H5



1508,
1564,
n-C4H9
n-C3H7



1509,
1565,
n-C4H9
n-C4H9



1510,
1566,
n-C4H9
n-C5H11



1511,
1567,
n-C4H9
n-C6H13



1512,
1568,
n-C4H9
n-C7H15



1513,
1569,
n-C5H11
CH3



1514,
1570,
n-C5H11
C2H5



1515,
1571,
n-C5H11
n-C3H7



1516,
1572,
n-C5H11
n-C4H9



1517,
1573,
n-C5H11
n-C5H11



1518,
1574,
n-C5H11
n-C6H13



1519,
1575,
n-C5H11
n-C7H15



1520,
1576,
n-C6H13
CH3



1521,
1577,
n-C6H13
C2H5



1522,
1578,
n-C6H13
n-C3H7



1523,
1579,
n-C6H13
n-C4H9



1524,
1580,
n-C6H13
n-C5H11



1525,
1581,
n-C6H13
n-C6H13



1526,
1582,
n-C6H13
n-C7H15



1527,
1583,
n-C7H15
CH3



1528,
1584,
n-C7H15
C2H5



1529,
1585,
n-C7H15
n-C3H7



1530,
1586,
n-C7H15
n-C4H9



1531,
1587,
n-C7H15
n-C5H11



1532,
1588,
n-C7H15
n-C6H13



1533,
1589,
n-C7H15
n-C7H15










The following are prepared analogously to Example A:


Example 1534-1533



embedded image


Example 1590-1645













embedded image

















Example No.

R1
R2
















1534,
1590,
H
CH3



1535,
1591,
H
C2H5



1536,
1592,
H
n-C3H7



1537,
1593,
H
n-C4H9



1538,
1594,
H
n-C5H11



1539,
1595,
H
n-C6H13



1540,
1596,
H
n-C7H15



1541,
1597,
CH3
CH3



1542,
1598,
CH3
C2H5



1543,
1599,
CH3
n-C3H7



1544,
1600,
CH3
n-C4H9



1545,
1601,
CH3
n-C5H11



1546,
1602,
CH3
n-C6H13



1547,
1603,
CH3
n-C7H15



1548,
1604,
C2H5
CH3



1549,
1605,
C2H5
C2H5



1550,
1606,
C2H5
n-C3H7



1551,
1607,
C2H5
n-C4H9



1552,
1608,
C2H5
n-C5H11



1553,
1609,
C2H5
n-C6H13



1554,
1610,
C2H5
n-C7H15



1555,
1611,
n-C3H7
CH3



1556,
1612,
n-C3H7
C2H5



1557,
1613,
n-C3H7
n-C3H7



1558,
1614,
n-C3H7
n-C4H9



1559,
1615,
n-C3H7
n-C5H11



1560,
1616,
n-C3H7
n-C6H13



1561,
1617,
n-C3H7
n-C7H15



1562,
1618,
n-C4H9
CH3



1563,
1619,
n-C4H9
C2H5



1564,
1620,
n-C4H9
n-C3H7



1565,
1621,
n-C4H9
n-C4H9



1566,
1622,
n-C4H9
n-C5H11



1567,
1623,
n-C4H9
n-C6H13



1568,
1624,
n-C4H9
n-C7H15



1569,
1625,
n-C5H11
CH3



1570,
1626,
n-C5H11
C2H5



1571,
1627,
n-C5H11
n-C3H7



1572,
1628,
n-C5H11
n-C4H9



1573,
1629,
n-C5H11
n-C5H11



1574,
1630,
n-C5H11
n-C6H13



1575,
1631,
n-C5H11
n-C7H15



1576,
1632,
n-C6H13
CH3



1577,
1633,
n-C6H13
C2H5



1578,
1634,
n-C6H13
n-C3H7



1579,
1635,
n-C6H13
n-C4H9



1580,
1636,
n-C6H13
n-C5H11



1581,
1637,
n-C6H13
n-C6H13



1582,
1638,
n-C6H13
n-C7H15



1583,
1639,
n-C7H15
CH3



1584,
1640,
n-C7H15
C2H5



1585,
1641,
n-C7H15
n-C3H7



1586,
1642,
n-C7H15
n-C4H9



1587,
1643,
n-C7H15
n-C5H11



1588,
1644,
n-C7H15
n-C6H13



1589,
1645,
n-C7H15
n-C7H15










Measurements for selected Examples:


Example No. 1612



embedded image


Phase behavior: C 124 I. Δ∈=6.6; Δn 0.135.

Claims
  • 1. A compound of the general formula I:
  • 2. A compound as claimed in claim 1, wherein e is 1, and is a C—C single bond.
  • 3. A compound as claimed in claim 1, wherein Y2 and Y3 are hydrogen.
  • 4. A compound as claimed in claim 1, wherein Y1 is F, Cl or CF3.
  • 5. A compound as claimed in claim 1, wherein A1, A2, A3 and A4 independently of one another are selected from the group comprising
  • 6. A compound as claimed in claim 1, wherein Z1, Z2, Z3 and Z4 independently of one another are a single bond, —CF2O— r —OCF2—.
  • 7. A compound as claimed in claim 1, wherein R1 is hydrogen, fluorine, alkanyl or alkoxy having 1 to 8 carbon atoms; andR2 is hydrogen, fluorine, alkanyl or alkoxy having 1 to 8 carbon atoms.
  • 8. A compound as claimed in claim 1, wherein a+b+c+d is 1 or 2, where a +b is 0 or 1 and c+d is 0 or 1.
  • 9. A compound as claimed in claim 2, wherein a and dare both 0;b is 0 or 1;c is 1;R1, if b is 0, is alkanyl or alkoxy, and if b is 1, is F, alkanyl or alkoxy;R2 is alkanyl or alkoxy;A2, if b is 1, is
  • 10. A compound of the general formula II
  • 11. A process for the preparation of compounds of the formula I as claimed in claim 1, wherein a compound of the formula II
  • 12. The process as claimed in claim 11, wherein the fluoride-releasing compound is HF, pyridine-hydrogen fluoride complexes, triethylamine trishydrofluoride (Et3N·3HF) or tetrabutylammonium dihydrogen-trifluoride; and the oxidant is dimethyldibromohydantoin (DBH), N-chlorosuccinimide (NCS), N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), chlorine, bromine, SO2, Cl2, SO2ClF, NOBF4 or chloramine T.
  • 13. The process as claimed in claim 11, wherein the compound of the formula II in which W1 and W2 are —S—W3—S— and W3 as defined in claim 11, is prepared by reaction of a lactone of the general formula III
  • 14. A liquid crystalline medium having at least two liquid crystalline compounds, comprising at least one compound of formula I as claimed in claim 1.
  • 15. An electrooptical display element, comprising a liquid crystalline medium as claimed in claim 14.
Priority Claims (1)
Number Date Country Kind
10 2004 036 831 Jul 2004 DE national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/EP2005/007221 7/5/2005 WO 00 11/26/2007
Publishing Document Publishing Date Country Kind
WO2006/012965 2/9/2006 WO A
US Referenced Citations (6)
Number Name Date Kind
5414006 Rendenbach-Mueller et al. May 1995 A
5849217 Nakamura et al. Dec 1998 A
6099759 Chan Aug 2000 A
7247355 Sagou et al. Jul 2007 B2
20050247910 Sugiura et al. Nov 2005 A1
20060177603 Taugerbeck et al. Aug 2006 A1
Foreign Referenced Citations (9)
Number Date Country
199 09 760 Oct 1999 DE
10 2004 053279 Jun 2005 DE
0594036 Apr 1994 EP
0 666 262 Aug 1995 EP
0 916 715 May 1999 EP
1 491 612 Dec 2004 EP
06256339 Dec 1994 JP
07145371 Oct 1995 JP
WO 2004076438 Sep 2004 WO
Related Publications (1)
Number Date Country
20080071097 A1 Mar 2008 US